AU2011203285B2

AU2011203285B2 - Enzymatic Oil-Degumming Method

Info

Publication number: AU2011203285B2
Application number: AU2011203285A
Authority: AU
Inventors: Jorn Borch Soe; Mark Turner
Original assignee: DuPont Nutrition Biosciences ApS
Current assignee: DuPont Nutrition Biosciences ApS
Priority date: 2004-07-16
Filing date: 2011-07-05
Publication date: 2013-09-05
Anticipated expiration: 2025-07-18
Also published as: AU2011203285A1

Abstract

Abstract A process of enzymatic degumming edible oils, comprising treating the edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, wherein the acyl acceptor may be 5 any compound comprising a hydroxy group. In one embodiment preferably the acyl acceptor is water and in another embodiment preferably the acyl acceptor is one or more stenols and/or stanols. When the acyl acceptor is a stanol and/or stenol, one or more sterol esters and/or stanol esters are produced. The lipid acyltransferase for use in the process of the present invention may comprises one 10 or more of the following amino acid sequences: SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14 or SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 45, SEQ 15 ID No. 47, SEQ ID No. 50 or an amino acid sequence which has 75% or more identity thereto. A novel lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16 is also taught.

Description

WO 2006/008508 PCT/GB2005/002823 ENZYMATIC OIL-DEGUMMING METHOD REFERENCE TO RELATED APPLICATIONS Reference is made to the following related applications: United States Application 5 Serial Number 09/750,990 filed on 20 July 1999, United States Application Serial Number 10/409,391, W02004/064537, W02004/064987, PCT/IB2004/004378 and PCT/IB2004/004374. Each of these applications and each of the documents cited in each of these applications ("application cited documents"), and each document referenced or cited in the application cited documents, either in the text or during the 10 prosecution of those applications, as well as all arguments in support of patentability advanced during such prosecution, are hereby incorporated herein by reference. Various documents are also cited in this text ("herein cited documents"). Each of the herein cited documents, and each document cited or referenced in the herein cited documents, is hereby incorporated herein by reference. 15 FIELD OF INVENTION The present invention relates to a method for enzymatically degumming edible oils using a lipid acyltransferase. 20 The present invention further relates to one or more lipid acyltransferases. The present invention yet further relates to the use of a lipid acyltransferase to the degumming of edible oils. 25 TECHNICAL BACKGROUND Traditionally two processes have been used for degumming of oil which are the physical degumming and the chemical degumming processes. Back in the 1990's the 30 enzymatic degumming process was developed based on the use of pancreatic phospholipase. Because this enzyme was non-kosher the phospholipase was eventually WO 2006/008508 PCT/GB2005/002823 2 substituted by a microbial phospholipase Al (Lecitase UltraTM - Novozymes, Denmark). The enzymatic process has several advantages over the chemical or the physical degumming processes including cost savings, higher yield and a more environmentally friendly process. 5 SUMMARY ASPECTS OF THE PRESENT INVENTION In one aspect, the present invention provides a method for the enzymatic degumming of vegetable oils or edible oils using a lipid acyltransferase as defined herein. 10 The present invention also provides a process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a lipid acyl transferase according to the present invention so as to remove a major part of the phospholipid. 15 The present invention also provides a process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a lipid acyl transferase according to the present invention so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, for example to one or 20 more sterols and/or stanols. In another aspect, the present invention provides one or more lipid acyltransferases. In one aspect, the present invention provides a lipid acyltransferase comprising the 25 amino acid sequence shown as SEQ ID No. 16. In another aspect, the present invention provides a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16, or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more 30 preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16.

WO 2006/008508 PCT/GB2005/002823 3 In a yet further aspect, the present invention provides the use of a lipid acyltransferase in the degumming of edible oils (i) to remove phospholipids (such as phosphatidylcholine) and/or (ii) to increase the formation of sterol esters and/or stanol esters in the oil and/or (iii) to remove phospholipids (such as phosphatidylcholine) 5 and/or to increase the formation of sterol esters and/or stanol esters in the oil without significantly increasing free fatty acids in the oil. PREFERABLE ASPECTS 10 The lipid acyltransferase for use in the present invention may be a natural lipid acyltransferase or may be a variant lipid acyltransferase. For instance, the lipid acyltransferase for use in the method and uses of the present invention may be one as described in W02004/064537 or W02004/064987, or 15 PCT/IB2004/004378 or GB0513859.9, for example. The term "lipid acyltransferase" as used herein means an enzyme that has acyltransferase activity (generally classified as E.C. 2.3.1.x), whereby the enzyme is capable of transferring an acyl group from a lipid to one or more acceptor substrates, 20 such as one or more of the following: a sterol; a stanol; a carbohydrate; a protein; a protein subunit; glycerol - preferably a sterol and/or a stanol. Preferably, the lipid acyltransferase according to the present invention or for use in the methods and/or uses of the present invention is capable of transferring an acyl group 25 from a lipid (as defined herein) to one or more of the following acyl acceptor substrates: a sterol or a stanol, preferably a sterol. For some aspects the "acyl acceptor" according to the present invention may be any compound comprising a hydroxy group (-OH1), such as for example, polyvalent 30 alcohols, including glycerol; sterols; stanols; carbohydrates; hydroxy acids including fruit acids, citric acid, tartaric acid, lactic acid and ascorbic acid; proteins or a sub-unit thereof, such as amino acids, protein hydrolysates and peptides (partly hydrolysed WO 2006/008508 PCT/GB2005/002823 4 protein) for example; and mixtures and derivatives thereof. Preferably, the "acyl acceptor" according to the present invention is not water. The acyl acceptor is preferably not a monoglyceride. 5 In one aspect, the lipid acyltransferase according to the present invention or for use in the methods and/or uses of the present invention may, as well as being able to transfer an acyl group from a lipid to a sterol and/or a stanol, additionally be able to transfer the acyl group from a lipid to one or more of the following: a carbohydrate, a protein, a 10 protein subunit, glycerol. Preferably, the lipid substrate upon which the lipid acyltransferase according to the present invention acts is one or more of the following lipids: a phospholipid, such as a lecithin, e.g. phosphatidylcholine. 15 This lipid substrate may be referred to herein as the "lipid acyl donor". The term lecithin as used herein encompasses phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and phosphatidylglycerol. 20 For some aspects, preferably the lipid substrate upon which the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention acts as a phospholipid, such as lecithin, for example phosphatidylcholine. For some aspects, preferably the lipid acyltransferase according to the present 25 invention or for use in the method and/or uses of the present invention is incapable, or substantially incapable, of acting on a triglyceride and/or a 1-monoglyceride and/or 2 monoglyceride. Suitably, the lipid acyltransferase according to the present invention or for use in the 30 method and/or uses of the present invention may exhibit one or more of the following phospholipase activities: phospholipase A2 activity (E.C. 3.1.1.4) or phospholipase Al activity (E.C. 3.1.1.32).

WO 2006/008508 PCT/GB2005/002823 5 Suitably, for some aspects the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention may be capable of transferring an acyl group from a phospholipid to a sterol and/or a stanol. 5 For some aspects, preferably the lipid acyltransferase according to the present invention or for use in methods and/or uses of the present invention is capable of transferring an acyl group from a phospholipid to a sterol and/or a stanol to form at least a sterol ester and/or a stanol ester. 10 For some aspects, preferably the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention does not exhibit triacylglycerol lipase activity (E.C. 3.1.1.3) or does not exhibit significant triacylglycerol lipase activity (E.C. 3.1.1.3). 15 The lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention may be capable of transferring an acyl group from a lipid to a sterol and/or a stanol. Thus, in one embodiment the "acyl acceptor" according to the present invention may be either a sterol or a stanol or a combination 20 of both a sterol and a stanol. Preferably, the lipid acyltransferase enzyme according to the present invention or for use in methods and uses of the present invention may be characterised using the following criteria: 25 (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to an acyl acceptor to form a new ester; and (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein 30 X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.

WO 2006/008508 PCT/GB2005/002823 6 Preferably, X of the GDSX motif is L or Y. More preferably, X of the GDSX motif is L. Thus, preferably the enzyme according to the present invention comprises the amino acid sequence motif GDSL. 5 The GDSX motif is comprised of four conserved amino acids. Preferably, the serine within the motif is a catalytic serine of the lipid acyltransferase enzyme. Suitably, the serine of the GDSX motif may be in a position corresponding to Ser-16 in Aeromonas hydrophila lipolytic enzyme taught in Brumlik & Buckley (Journal of Bacteriology Apr. 1996, Vol. 178, No. 7, p 2060-2064). 10 To determine if a protein has the GDSX motif according to the present invention, the sequence is preferably compared with the hidden markov model profiles (HMM profiles) of the pfam database in accordance with the procedures taught in W02004/064537 or W02004/064987. 15 Pfam is a database of protein domain families. Pfam contains curated multiple sequence alignments for each family as well as profile hidden Markov models (profile HMMs) for identifying these domains in new sequences. An introduction to Pfam can be found in Bateman A et al. (2002) Nucleic Acids Res. 30; 276-280. Hidden Markov 20 models are used in a number of databases that aim at classifying proteins, for review see Bateman A and Haft DH (2002) Brief Bioinform 3; 236-245. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list-uids =12230032&dopt=Abstract 25 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&listuids =1 1752314&dopt=Abstract For a detailed explanation of hidden Markov models and how they are applied in the Pfam database see Durbin R, Eddy S, and Krogh A (1998) Biological sequence 30 analysis; probabilistic models of proteins and nucleic acids. Cambridge University Press, ISBN 0-521-62041-4. The Hammer software package can be obtained from Washington University, St Louis, USA.

WO 2006/008508 PCT/GB2005/002823 7 Alternatively, the GDSX motif can be identified using the Hammer software package, the instructions are provided in Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge 5 University Press, ISBN 0-521-62041-4 and the references therein, and the HMMER2 profile provided within this specification. The PFAM database can be accessed, for example, through several servers which are currently located at the following websites. 10 http://www.sanger.ac.uk/Software/Pfam/index.shtml http://pfam.wustl.edu/ http://pfam.jouy.inra.fr/ http://pfam.cgb.ki.se/ 15 The database offers a search facility where one can enter a protein sequence. Using the default parameters of the database the protein sequence will then be analysed for the presence of Pfam domains. The GDSX domain is an established domain in the database and as such its presence in any query sequence will be recognised. The database will return the alignment of the Pfam00657 consensus sequence to the query 20 sequence. Preferably the lipid acyltransferase enzyme for use in methods and uses of the invention can be aligned using the Pfam00657 consensus sequence (for a full explanation see W02004/064537 or W02004/064987). 25 Preferably, a positive match with the hidden markov model profile (HMM profile) of the pfam00657 domain family indicates the presence of the GDSL or GDSX domain according to the present invention. 30 Preferably when aligned with the Pfam00657 consensus sequence the lipid acyltransferase for use in the methods or uses of the invention may have at least one, preferably more than one, preferably more than two, of the following, a GDSx block, a WO 2006/008508 PCT/GB2005/002823 8 GANDY block, a HPT block. Suitably, the lipid acyltransferase may have a GDSx block and a GANDY block. Alternatively, the enzyme may have a GDSx block and a HPT block. Preferably the enzyme comprises at least a GDSx block. 5 Preferably, residues of the GANDY motif are selected from GANDY, GGNDA, GGNDL, most preferably GANDY. Preferably, when aligned with the Pfam00657 consensus sequence the enzyme for use in the methods or uses of the invention have at least one, preferably more than one, 10 preferably more than two, preferably more than three, preferably more than four, preferably more than five, preferably more than six, preferably more than seven, preferably more than eight, preferably more than nine, preferably more than ten, preferably more than eleven, preferably more than twelve, preferably more than thirteen, preferably more than fourteen, of the following amino acid residues when 15 compared to the reference A. hydrophilia polypeptide sequence, namely SEQ 1D No. 1: 28hid, 29hid, 30hid, 31hid, 32gly, 33Asp, 34Ser, 35hid, 130hid, 131Gly, 132Hid, 133Asn, 134Asp, 135hid, 309His. The pfam00657 GDSX domain is a unique identifier which distinguishes proteins 20 possessing this domain from other enzymes. The pfam00657 consensus sequence is presented in Figure 12 as SEQ ID No. 2. This is derived from the identification of the pfam family 00657, database version 6, which may also be referred to as pfam00657.6 herein. 25 The consensus sequence may be updated by using further releases of the pfam database (for example see W02004/064537 or W02004/064987). The presence of the GDSx, GANDY and HPT blocks are found in the pfam family 30 00657 from both releases of the database. Future releases of the pfam database can be used to identify the pfam family 00657.

WO 2006/008508 PCT/GB2005/002823 9 In one embodiment, the lipid acyltransferase enzyme for use in methods and uses of the present invention may be characterised using the following criteria: (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of 5 a lipid acyl donor is transferred to acyl acceptor to form a new ester; (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.; (iii) the enzyme comprises His-309 or comprises a histidine residue at a 10 position corresponding to His-309 in the Aeromonas hydrophila lipid acyltransferase enzyme shown in Figures 11 and 13 (SEQ ID No. 1 or SEQ ID No. 3). Preferably, the amino acid residue of the GDSX motif is L. 15 In SEQ ID No. 3 or SEQ ID No. 1 the first 18 amino acid residues form a signal sequence. His-309 of the full length sequence, that is the protein including the signal sequence, equates to His-291 of the mature part of the protein, i.e. the sequence without the signal sequence. 20 In one embodiment, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises the following catalytic triad: Ser-34, Asp-134 and His 309 or comprises a serine residue, an aspartic acid residue and a histidine residue, respectively, at positions corresponding to Ser-34, Asp- 134 and His-309 in the 25 Aeromonas hydrophila lipid acyltransferase enzyme shown in Figure 13 (SEQ ID No. 3) or Figure 11 (SEQ ID No. 1). As stated above, in the sequence shown in SEQ ID No. 3 or SEQ ID No. 1 the first 18 amino acid residues form a signal sequence. Ser-34, Asp-134 and His-309 of the full length sequence, that is the protein including the signal sequence, equate to Ser-16, Asp-i 16 and His-291 of the mature part of the 30 protein, i.e. the sequence without the signal sequence. In the pfam00657 consensus sequence, as given in Figure 12 (SEQ ID No. 2) the active site residues correspond to Ser-7, Asp-157 and His-348.

WO 2006/008508 PCT/GB2005/002823 10 In one embodiment, the lipid acyltransferase enzyme for use in methods and uses of the present invention may be characterised using the following criteria: (i) the enzyme possesses acyl transferase activity which may be defined as 5 ester transfer activity whereby the acyl part of an original ester bond of a first lipid acyl donor is transferred to an acyl acceptor to form a new ester; and (ii) the enzyme comprises at least Gly-32, Asp-33, Ser-34, Asp-134 and His-309 or comprises glycine, aspartic acid, serine, aspartic acid and 10 histidine residues at positions corresponding to Gly-32, Asp-33, Ser-34, Asp-134 and His-309, respectively, in the Aeromonas hydrophila lipid acyltransferase enzyme shown in Figure 13 (SEQ ID No. 3) or Figure 11 (SEQ ID No. 1). 15 Suitably, the lipid acyltransferase enzyme for use in methods and uses of present invention comprises one or more of the following amino acid sequences: (i) the amino acid sequence shown as SEQ ID No. 3 (see Figure 13) (ii) the amino acid sequence shown as SEQ ID No. 4 (see Figure 14) (iii) the amino acid sequence shown as SEQ ID No. 5 (see Figure 15) 20 (iv) the amino acid sequence shown as SEQ ID No. 6 (see Figure 16) (v) the amino acid sequence shown as SEQ ID No. 7 (see Figure 17) (vi) the amino acid sequence shown as SEQ ID No. 8 (see Figure 18) (vii) the amino acid sequence shown as SEQ ID No. 9 (Figure 19) (viii) the amino acid sequence shown as SEQ ID No. 10 (Figure 20) 25 (ix) the amino acid sequence shown as SEQ ID No. 11 (Figure 21) (x) the amino acid sequence shown as SEQ ID No. 12 (Figure 22) (xi) the amino acid sequence shown as SEQ ID No. 13 (Figure 23) (xii) the amino acid sequence shown as SEQ ID No. 14 (Figure 24) (xiii) the amino acid sequence shown as SEQ ID No. 1 (Figure 11) 30 (xiv) the amino acid sequence shown as SEQ ID No. 15 (Figure 25) or an amino acid sequence which has 75% or more identity with any one of the sequences shown as SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, WO 2006/008508 PCT/GB2005/002823 11 SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, or SEQ ID No. 15. Suitably, the lipid acyltransferase enzyme for use in methods and uses of the present 5 invention comprises either the amino acid sequence shown as SEQ ID No. 3 or as SEQ ID No. 4 or SEQ ID No. 1 or SEQ ID No. 15 or comprises an amino acid sequence which has 75% or more, preferably 80% or more, preferably 85% or more, preferably 90% or more, preferably 95% or more, identity with the amino acid sequence shown as SEQ ID No. 3 or the amino acid sequence shown as SEQ ID No. 4 or the amino acid 10 sequence shown as SEQ ID No. 1 or the amino acid sequence shown as SEQ ID No. 15. Suitably the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises an amino acid sequence which has 80% or more, preferably 85% 15 or more, more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, or SEQ ID No. 15. 20 Suitably, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises one or more of the following amino acid sequences: (a) an amino acid sequence shown as amino acid residues 1-100 of SEQ ID No. 3 or SEQ ID No. 1; 25 (b) an amino acid sequence shown as amino acids residues 101-200 of SEQ ID No. 3 or SEQ ID No. 1; (c) an amino acid sequence shown as amino acid residues 201-300 of SEQ ID No. 3 or SEQ ID No. 1; or (d) an amino acid sequence which has 75% or more, preferably 85% or more, more 30 preferably 90% or more, even more preferably 95% or more identity to any one of the amino acid sequences defined in (a)-(c) above.

WO 2006/008508 PCT/GB2005/002823 12 Suitably, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises one or more of the following amino acid sequences: (a) an amino acid sequence shown as amino acid residues 28-39 of SEQ ID No. 3 or SEQ ID No. 1; 5 (b) an amino acid sequence shown as amino acids residues 77-88 of SEQ ID No. 3 or SEQ ID No. 1; (c) an amino acid sequence shown as amino acid residues 126-136 of SEQ ID No. 3 or SEQ ID No. 1; (d) an amino acid sequence shown as amino acid residues 163-175 of SEQ ID No. 3 or 10 SEQ ID No. 1; (e) an amino acid sequence shown as amino acid residues 304-311 of SEQ ID No. 3 or SEQ ID No. 1; or (f) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of 15 the amino acid sequences defined in (a)-(e) above. In one aspect, the lipid acyltransferase for use in the method and uses of the present invention may be the lipid acyl transferase from Candida parapsilosis as taught in EP 1 275 711. Thus in one aspect the lipid acyltransferase for use in the method and uses 20 of the present invention may be a lipid acyltransferase comprising one of the amino acid sequences taught in SEQ ID No. 17 (Figure 28) or SEQ ID No. 18 (Figure 29). Much by preference, the lipid acyltransferase for use in the method and uses of the present invention may be a lipid acyltransferase comprising the amino acid sequence 25 shown as SEQ ID No. 16 (Figure 10), or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16. This enzyme could be considered a variant enzyme. 30 In one aspect, the lipid acyltransferase for use in the methods and uses of the present invention may be a lecithin:cholesterol acyltransferase (LCAT) or variant thereof (for example a variant made by molecular evolution) WO 2006/008508 PCT/GB2005/002823 13 Suitable LCATs are known in the art and may be obtainable from one or more of the following organisms for example: mammals, rat, mice, chickens, Drosophila melanogaster, plants, including Arabidopsis and Oryza sativa, nematodes, fungi and 5 yeast. In one embodiment the lipid acyltransferase enzyme for use in the methods and uses of the present invention may be the lipid acyltransferase obtainable, preferably obtained, from the E. coli strains TOP 10 harbouring pPetl2aAhydro and pPetl2aASalmo 10 deposited by Danisco A/S of Langebrogade 1, DK- 1001 Copenhagen K, Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 22 December 2003 under accession numbers NICMB 41204 and 15 NCIMB 41205, respectively. Highly preferred lipid acyl transferases for use in the methods of the invention include those isolated from Aeromonas spp., preferably Aeromonas hydrophila or A. salmonicida, most preferable A. salmonicida. Most preferred lipid acyl transferases 20 for use in the present invention are encoded by SEQ ID No.s 1, 3, 4, 15, 16. It will be recognised by the skilled person that it is preferable that the signal peptides of the acyl transferase has been cleaved during expression of the transferase. The signal peptide of SEQ ID 1, 3, 4, 15 and 16 are amino acids 1-18. Therefore the most preferred regions are amino acids 19-335 for SEQ ID No. 1 and SEQ ID No. 3 (A. hydrophilia) 25 and amino acids 19-336 for SEQ ID No. 4, SEQ ID No. 15 and SEQ ID No. 16. (A. salmonicida). When used to determine the homology of identity of the amino acid sequences, it is preferred that the alignments as herein described use the mature sequence. 30 Therefore the most preferred regions for determining homology (identity) are amino acids 19-335 for SEQ ID No. 1 and 3 (A. hydrophilia) and amino acids 19-336 for SEQ ID No.s 4, 15 and 16. (A. salmonicida). SEQ ID 34 and 35 are mature protein WO 2006/008508 PCT/GB2005/002823 14 sequences of the highly preferred lipid acyl transferases from A. hydrophilia and A. salmonicida respectively. A lipid acyl transferase for use in the invention may also be isolated from 5 Thermobgifda, preferably T. fisca, most preferably that encoded by SEQ ID No. 28. A lipid acyl transferase for use in the invention may also be isolated from Streptomyces, preferable S. avermitis, most preferably that encoded by SEQ ID No. 32. Other possible enzymes for use in the present invention from Streptomyces include 10 those encoded by SEQ ID No.s 5, 6, 9, 10, 11, 12, 13, 14, 31, 33. Theexamples show that the enzyme encoded by SEQ ID No. 33 is highly effective in enzymatic degumming. An enzyme for use in the invention may also be isolated from Corynebacterium, 15 preferably C. efficiens, most preferably that encoded by SEQ ID No. 29. Suitably, the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of the amino acid sequences shown as SEQ ID No.s 37, 38, 40, 41, 43, 45, or 47 or an amino acid 20 sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No.s 36, 39, 42, 44, 46, or 48 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith. 25 Preferably, the lipid acyltransferase for use in the methods and uses according to the present invention is a lipid acyltransferase capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Streptomyces species. 30 In one embodiment the lipid acyltransferase for use in the methods and uses according to the present invention is preferably a lipid acyltransferase capable of hydrolysing at WO 2006/008508 PCT/GB2005/002823 15 least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 36; 5 b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 36 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 36. 10 In one embodiment, the lipid acyltransferase for use in the methods and uses according to the present invention is preferably a lipid acyltransferase comprising an amino acid sequence as shown in SEQ ID No. 37 or an amino acid sequence which has at least 60% identity thereto. 15 In another embodiment the lipid acyltransferase for use in the methods and uses according to the present invention is preferably a lipid acyltransferase capable of hydrolysing at least a galactolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme comprises an amino acid sequence as shown in SEQ ID No. 37 or an amino acid 20 sequence which has at least 60% identity thereto. Preferably, the lipid acyltransferase for use in the methods and uses according to the present invention is a lipid acyltransferase capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more 25 acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Thermobifida species, preferably Thermobifidafusca. Preferably, the lipid acyltransferase for use in the methods and uses according to the present invention is a lipolytic enzyme capable of hydrolysing at least galactolipids 30 and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from Corynebacterium species, preferably Corynebacterium efficiens.

WO 2006/008508 PCT/GB2005/002823 16 In a further embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of the amino acid sequences shown as SEQ ID No. 37, 38, 40, 41, 43, 45 or 47 or an 5 amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 39, 42, 44, 46 or 48 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith. 10 In a further embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of amino sequences shown as SEQ ID No. 38, 40, 41, 45 or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein. 15 In a further embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of amino sequences shown as SEQ ID No. 38, 40, or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity 20 therewith for the uses described herein. More preferably in one embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 47 or an amino acid sequence which 25 has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith. In another embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 43 or 44 or an amino acid sequence which has at 30 least 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

WO 2006/008508 PCT/GB2005/002823 17 In another embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 41 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith. 5 In one embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid 10 selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 36; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 36 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% 15 identity with the nucleotide sequence shown in SEQ ID No. 36. In one embodiment the lipid acyltransferase according to the present invention may be a lipid acyltransferase obtainable, preferably obtained, from the Streptomyces strains L130 or L131 deposited by Danisco A/S of Langebrogade 1, DK-1001 Copenhagen K, 20 Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 25 June 2004 under accession numbers NCIMB 41226 and NCIMB 41227, respectively. 25 Suitable lipid acyltransferases for use in accordance with the present invention and/or in the methods of the present invention may comprise any one of the following amino acid sequences and/or be encoded by the following nucleotide sequences: a polynucleotide encoding a lipid acyltransferase according to the present invention 30 (SEQ ID No. 16); an amino acid sequence of a lipid acyltransferase according to the present invention (SEQ ID No. 17).

WO 2006/008508 PCT/GB2005/002823 18 A suitable lipid acyl-transferase enzyme for use in the methods of the invention may also be identified by alignment to the Li 31 (SEQ ID No. 37) sequence using Align X, the Clustal W pairwise alignment algorithm of VectorNTI using default settings. 5 An alignment of the Ll 31 and homologues from S. avermitilis and T. fusca illustrates that the conservation of the GDSx motif (GDSY in L131 and S. avermitilis and T. fusca), the GANDY box, which is either GGNDA or GGNDL, and the HPT block (considered to be the conserved catalytic histadine). These three conserved blocks are 10 highlighted in Figure 61. When aligned to either the pfam Pfam00657 consensus sequence (as described in W004/064987) and/ or the L131 sequence herein disclosed (SEQ ID No 37) it is possible to identify three conserved regions, the GDSx block, the GANDY block and 15 the HTP block (see W004/064987 for further details). When aligned to either the pfam Pfam00657 consensus sequence (as described in W004/064987) and/ or the L131 sequence herein disclosed (SEQ ID No 37) i) The lipid acyl-transferase enzyme of the invention, or for use in methods of 20 the invention, has preferably a GDSx motif, more preferably a GDSx motif selected from GDSL or GDSY motif. and/or ii) The lipid acyl-transferase enzyme of the invention, or for use in methods of the invention, has preferably a GANDY block, more preferably a GANDY 25 block comprising amino GGNDx, more preferably GGNDA or GGNDL. and/or iii) The enzyme of the invention, or for use in methods of the invention, has preferable an HTP block. and preferably 30 iv) The galactolipase/lipid acyl-transferase enzyme of the invention, or for use in methods of the invention, has preferably a GDSx or GDSY motif, and a WO 2006/008508 PCT/GB2005/002823 19 GANDY block comprising amino GGNDx, preferably GGNDA or GGNDL, and a HTP block (conserved histadine). Suitably, when the lipid acyltransferase for use in the methods or uses of the present 5 invention, may be a variant lipid acyltransferase, in which case the enzyme may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, 1, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid 10 residues defined in set 2 or set 4 or set 6 or set 7 (defined hereinbelow). For instance the variant lipid acyltransferase enzyme for use in the methods or uses of the present invention may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid 15 residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues detailed in set 2 or set 4 or set 6 or set 7 (defined hereinbelow) identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by 20 structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as taught herein. In a further embodiment the variant lipid acyltransferase enzyme for use in the methods or uses of the present invention may be characterised in that the enzyme 25 comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 2 30 Figure 12) and modified according to a structural model of P10480 to ensure best fit overlap (see Figure 30) as taught herein.

WO 2006/008508 PCT/GB2005/002823 20 Suitably the variant lipid acyltransferase enzyme may comprise an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ D No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 5 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30,, SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (hereinafter defined) identified by sequence alignment with SEQ ID No. 34. 10 Alternatively the variant lipid acyltransferase enzyme may be a variant enzyme comprising an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ 15 ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30,, SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 identified by said parent sequence being structurally aligned with the structural model of P10480 20 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as taught herein. Alternatively, the variant lipid acyltransferase enzyme may be a variant enzyme comprising an amino acid sequence, which amino acid sequence is shown as SEQ ID 25 No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30,, SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one 30 or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 2) and modified according to WO 2006/008508 PCT/GB2005/002823 21 a structural model of P10480 to ensure best fit overlap (see Figure 30) as taught hereinbelow. The term "modifying" as used herein means adding, substituting and/or deleting. 5 Preferably the term "modifying" means "substituting". For the avoidance of doubt, when an amino acid is substituted in the parent enzyme it is preferably substituted with an amino acid which is different from that originally found at that position in the parent enzyme thus to produce a variant enzyme. In other 10 words, the term "substitution" is not intended to cover the replacement of an amino acid with the same amino acid. Preferably, the parent enzyme is an enzyme which comprises the amino acid sequence shown as SEQ ID No. 34 and/or SEQ ID No. 15 and/or SEQ ID No. 35. 15 Preferably, the variant enzyme is an enzyme which comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7. 20 In one embodiment, preferably the variant enzyme comprises one or more amino acid modifications compared with the parent sequence at at least one of the amino acid residues defined in set 4. 25 Suitably, the variant enzyme comprises one or more of the following amino acid modifications compared with the parent enzyme: S3E, A, G, K, M, Y, R, P, N, T or G E309Q, R or A, preferably Q or R -318Y, H, S or Y, preferably Y. 30 Preferably, X of the GDSX motif is L. Thus, preferably the parent enzyme comprises the amino acid motif GDSL.

WO 2006/008508 PCT/GB2005/002823 22 Preferably the method of producing a variant lipid acyltransferase enzyme further comprises one or more of the following steps: 1) structural homology mapping or 5 2) sequence homology alignment. Suitably, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (11VN.PDB) shown in 10 Figure 46; ii) selecting one or more amino acid residue within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set I or set 2); and iii) modifying one or more amino acids selected in accordance with step (ii) in said 15 parent sequence. In one embodiment the amino acid residue selected may reside within a 9, preferably within a 8, 7, 6, 5, 4, or 3 A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47). 20 Suitably, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (1 IVN.PDB) shown in Figure 46; 25 ii) selecting one or more amino acids within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2); iii) determining if one or more amino acid residues selected in accordance with step (ii) are highly conserved (particularly are active site residues and/or part of 30 the GDSx motif and/or part of the GANDY motif); and WO 2006/008508 PCT/GB2005/002823 23 iv) modifying one or more amino acids selected in accordance with step (ii), excluding conserved regions identified in accordance with step (iii) in said parent sequence. 5 In one embodiment the amino acid residue selected may reside within a 9, preferably within a 8, 7, 6, 5, 4, or 3 A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47). Alternatively to, or in combination with, the structural homology mapping described 10 above, the structural homology mapping can be performed by selecting specific loop regions (LRs) or intervening regions (1VRs) derived from the pfam alignment (Alignment 2, Figure 48) overlaid with the P10480 model and IIVN. The loop regions (LRs) or intervening regions (IVRs) are defined in the Table below: P10480 amino acid positions (SEQ ID No 34) IVR1 1-19 Loop1 (LR1) 20-41 IVR2 42-76 Loop2 (LR2) 77-89 IVR3 90-117 Loop3 (LR3) 118-127 IVR4 128-145 Loop4 (LR4) 146-176 IVR5 177-207 Loop5 (LR5) 208-287 IVR6 288-317 15 In some embodiments of the present invention the variant acyltransferase enzyme for use in the methods and uses of the present invention not only comprises an amino acid modifications at one or more of the amino acids defined in any one of sets 1-4 and 6-7, WO 2006/008508 PCT/GB2005/002823 24 but also comprises at least one amino acid modification in one or more of the above defined intervening regions (IVR1-6) (preferably in one or more of the IVRs 3, 5 and 6, more preferably in IVR 5 or IVR 6) and/or in one or more of the above-defined loop regions (LR1-5) (preferably in one or more of LRI, LR2 or LR5, more preferably in 5 LR5). In one embodiment, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only defined by one or more of set 2, 4, 6 and 7, but also is within one or more of the 10 IVRs 1-6 (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6) or within one or more of the LRs 1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5). Suitably, the variant acyltransferase for use in the methods and uses of the present 15 invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within IVR 3. Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set 20 1 or 2, but also is within IVR 5. Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within IVR 6. 25 Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within LR 1. 30 Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within LR 2.

WO 2006/008508 PCT/GB2005/002823 25 Likewise, in some embodiments of the present invention the variant acyltransferase enzyme for use in the methods and uses of the present invention not only comprises an amino acid modification at one or more amino acid residues which reside within a 10, 5 preferably within a 9, 8, 7, 6, 5, 4, or 3, A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47), but also comprises at least one amino acid modification in one or more of the above defined intervening regions (IVR1-6) (preferably in one or more of lVRs 3, 5 and 6, more preferably in IVR 5 or IVR 6) and/or in one or more of the above-defined loop regions (LR1 -5) (preferably in 10 one or more of LR1, LR2 or LR5, more preferably in LR5). In one embodiment, preferably the amino acid modification is at one or more amino acid residues which reside within a 1 OA sphere and also within LR5. 15 Thus, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 46; ii) selecting one or more amino acid residue within a 10A sphere centred on 20 the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2); and/or selecting one or more amino acid residues within IVRI-6) (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6); and/or selecting one or more amino acid residues within LR1-5 25 (preferably within LR1, LR2 or LR5, more preferably within LR5); and iii) modifying one or more amino acids selected in accordance with step (ii) in said parent sequence. In one embodiment the amino acid residue selected may reside within a 9 A sphere, 30 preferably within an 8, 7, 6, 5, 4, or 3 A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47).

WO 2006/008508 PCT/GB2005/002823 26 Suitably, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 46; 5 ii) selecting one or more amino acids within a 1OA sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2); and/or selecting one or more amino acid residues within IVR1-6) (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 10 6); and/or selecting one or more amino acid residues within LR1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5); iii) determining if one or more amino acid residues selected in accordance with step (ii) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and 15 modifying one or more amino acids selected in accordance with step (ii), excluding conserved regions identified in accordance with step (iii) in said parent sequence. Suitably, the one or more amino acids selected in the methods detailed above are not only within a 1 OA sphere centred on the central carbon atom of the glycerol molecule 20 in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set I or set 2), but are also within one or more of the IVRs 1-6 (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6) or within one or more of the LRs 1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5). 25 In one embodiment, preferably the one or more amino acid modifications is/are within LR5. When it is the case that the modification(s) is within LR5, the modification is not one which is defined in set 5. Suitably, the one or more amino acid modifications not only fall with the region defined by LR5, but also constitute an amino acid within one or more of set 2, set 4, set 6 or set 7. 30 Suitably, the sequence homology alignment may comprise one or more of the following steps: WO 2006/008508 PCT/GB2005/002823 27 i) selecting a first parent lipid acyltransferase; ii) identifying a second related lipid acyltransferase having a desirable activity; iii) aligning said first parent lipid acyltransferase and the second related lipid acyltransferase; 5 iv) identifying amino acid residues that differ between the two sequences; and v) modifying one or more of the amino acid residues identified in accordance with step (iv) in said parent lipid acyltransferase. Suitably, the sequence homology alignment may comprise one or more of the 10 following steps: i) selecting a first parent lipid acyltransferase; ii) identifying a second related lipid acyltransferase having a desirable activity; iii) aligning said first parent lipid acyltransferase and the second related lipid acyltransferase; 15 iv) identifying amino acid residues that differ between the two sequences; v) determining if one or more amino acid residues selected in accordance with step (iv) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and vi) modifying one or more of the amino acid residues identified in accordance with 20 step (iv) excluding conserved regions identified in accordance with step (v) in said parent sequence. Suitably, said first parent lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, 25 SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32 or SEQ ID No. 33. 30 Suitably, said second related lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 3, SEQ ID No. 34, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No.

WO 2006/008508 PCT/GB2005/002823 28 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32 or SEQ ID No. 33. 5 The variant enzyme must comprise at least one amino acid modification compared with the parent enzyme. In some embodiments, the variant enzyme may comprise at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10 amino acid modifications compared with the parent enzyme. 10 When referring to specific amino acid residues herein the numbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID No. 34 or SEQ ID No. 35. 15 In one aspect preferably the variant enzyme comprises one or more of the following amino acid substitutions: S3A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or L17A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or 20 S18A, C, D, E, F, H, I, K, L, M, N, P, Q, R, T, W, or Y; and/or K22A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or M23A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or Y3OA, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or G40A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or 25 N80A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or P81A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or K82A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or N87A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or N88A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or 30 W11A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; and/or VI 12A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or A1 14C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or WO 2006/008508 PCT/GB2005/002823 29 Y1 17A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or L118A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or P156A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or D157A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or 5 G159A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or Q160A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or N161A, C, D, E, F, G, H, I, K, L, M P, Q, R, S, T, V, W, or Y; and/or P162A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or S163A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or 10 A164C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or R165A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; and/or S166A, C, D, E, F, G, H, 1, K, L, M, N, P, Q, R, T, V, W, or Y; and/or Q167A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or K168A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or 15 V169A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or VI70A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or E171A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or A172C, D, E, F, G, H, , K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or Y179A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or 20 H180A, C, D, E, F, G, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or N181A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y ; and/or Q182A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y, preferably K; and/or M209A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or L210 A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or 25 R211 A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or N215 A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or Y226A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or Y230A, C, D, E, G, H, , , L, M, N, P, Q, R, S, T, V or W; and/or K284A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or 30 M285A, C, D, E, F, G, H, 1, K, L, N, P, Q, R, S, T, V, W, or Y; and/or Q289A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or V290A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or WO 2006/008508 PCT/GB2005/002823 30 E309A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or S310A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y. In addition or alternatively thereto there may be one or more C-terminal extensions. 5 Preferably the additional C-terminal extension is comprised of one or more aliphatic amino acids, preferably a non-polar amino acid, more preferably of I, L, V or G. Thus, the present invention further provides for a variant enzyme comprising one or more of the following C-terminal extensions: 3181, 318L, 318V, 318G. 10 When it is the case that the residues in the parent backbone differ from those in P10480 (SEQ ID No. 2), as determined by homology alignment and/or structural alignment to P10480 and/or I IVN, it may be desirable to replace the residues which align to any one or more of the following amino acid residues in P10480 (SEQ ID No. 2): Ser3, Leul7, Lys22, Met23, Gly4O, Asn8O, Pro8l, Lys82, Asn87, Asn88, Trpl11, 15 Vall2, Ala1l4, Tyr1l7, Leull8, Prol56, Gly159, Glnl6O, Asnl6l,Prol62, Serl63, Ala164, Arg165, Serl66, G1n167, Lys168, Va1169, Vall70, Glul7l, Ala172, Tyr179, His180, Asn181, Gln182, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289, Val290, Glu309 or Ser310, with the residue found in P10480 respectively. 20 Variant enzymes which have a decreased hydrolytic activity against a phospholipid, such as phosphatidylcholine (PC), may also have an increased transferase activity from a phospholipid. Variants enzymes which have an increased transferase activity from a phospholipid, 25 such as phosphatidylcholine (PC), may also have an increased hydrolytic activity against a phospholipid. Suitably, one or more of the following sites may be involved in substrate binding: Leul7; Alal 14; Tyrl79; Hisl80; Asn181; Met209; Leu210; Arg2l1; Asn215; Lys284; 30 Met285; Gln289; Val290.

WO 2006/008508 PCT/GB2005/002823 31 1. Modification of one or more of the following residues may result in a variant enzyme having an increased absolute transferase activity against phospholipid: S3, D157, S310, E309, Y179, N215, K22, Q289, M23, H180, M209, L210, R211, P81, 5 V1 12, N80, L82, N88; N87 Specific modifications which may provide a variant enzyme having an improved transferase activity from a phospholipid may be selected from one or more of the following: 10 S3A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably N, E, K, R, A, P or M, most preferably S3A D157A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y ; preferably D157S, R, E, N, G, T, V, Q, K or C S31OA, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably S31OT 15 -318 E E309A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably E309 R, E, L, R or A Y179A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or W; preferably Y179 D, T, E, R, N, V, K, Q or S, more preferably E, R, N, V, K or Q 20 N215A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N215 S, L, R or Y K22A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; preferably K22 E, R, C or A Q289A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; preferably Q289 R, E, 25 G, P or N M23A, C, D, E, F, G, H, I, K, L N, P, Q, R, S, T, V, W or Y; preferably M23 K, Q, L, G, T or S H180A, C, D, E, F, G, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably H180 Q, R or K M209 A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W or Y; preferably M209 Q, S, 30 R, A, N, Y, E, V or L L21OA, C, D, E, F, G, H, 1, K, M, N, P, Q, R, S, T, V, W or Y; preferably L210 R, A, V, S, T, I, W or M WO 2006/008508 PCT/GB2005/002823 32 R21 IA, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; preferably R21 1T P81A, C, D, E, F, G, H, , K, L, M, N, Q, R, S, T, V, W or Y; preferably P81G V1 12A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; preferably V1 12C N80A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N80 R, G, N, 5 D, P, T, E, V, A or G L82A, C, D, E, F, G, H, I, M, N, P, Q, R, S, T, V, W or Y; preferably L82N, S or E N88A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N88C N87A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N87M or G 10 Modification of one or more of the following residues results in a variant enzyme having an increased absolute transferase activity against phospholipid: S3 N, R, A, G M23 K, Q, L, G, T, S 15 H18OR L82 G Y179 E, R, N, V, K or Q E309 R, S, L or A 20 One preferred modification is NSOD. This is particularly the case when using the reference sequence SEQ ID No. 35. Therefore in a preferred embodiment of the present invention the lipid acyltransferase according to the present invention comprises SEQ ID No. 35. 25 As noted above, when referring to specific amino acid residues herein the numbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID No. 34 or SEQ ID No. 35 Much by preference, the lipid acyltransferase for use in the method and uses of the 30 present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16 (Figure 10), or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably WO 2006/008508 PCT/GB2005/002823 33 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16. This enzyme may be considered a variant enzyme. For the avoidance of doubt, when a particular amino acid is taught at a specific site, for 5 instance Li 18 for instance, this refers to the specific amino acid at residue number 118 in SEQ ID No. 34 unless otherwise stated. However, the amino acid residue at site 118 in a different parent enzyme may be different from leucine. Thus, when taught to substitute an amino acid at residue 118, although reference may 10 be made to Li 18 it would be readily understood by the skilled person that when the parent enzyme is other than that shown in SEQ ID No. 34, the amino acid being substituted may not be leucine. It is, therefore, possible that when substituting an amino acid sequence in a parent enzyme which is not the enzyme having the amino acid sequence shown as SEQ ID No. 34, the new (substituting) amino acid may be the 15 same as that taught in SEQ ID No. 34. This may be the case, for instance, where the amino acid at say residue 118 is not leucine and is, therefore different from the amino acid at residue 118 in SEQ ID No. 34. In other words, at residue 118 for example, if the parent enzyme has at that position an amino acid other than leucine, this amino acid may be substituted with leucine in accordance with the present invention. 20 For the purposes of the present invention, the degree of identity is based on the number of sequence elements which are the same. The degree of identity in accordance with the present invention may be suitably determined by means of computer programs 25 known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, US537 11) (Needleman & Wunsch (1970), J. of Molecular Biology 48, 443-45) using the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension 30 penalty of 0.1. Suitably, the degree of identity with regard to an amino acid sequence is determined over at least 20 contiguous amino acids, preferably over at least 30 contiguous amino acids, preferably over at least 40 contiguous amino acids, preferably WO 2006/008508 PCT/GB2005/002823 34 over at least 50 contiguous amino acids, preferably over at least 60 contiguous amino acids. Suitably, the lipid acyltransferase enzyme according to the present invention may be 5 obtainable, preferably obtained, from organisms from one or more of the following genera: Aeromonas, Streptomyces, Saccharomyces, Lactococcus, Mycobacterium, Streptococcus, Lactobacillus, Desulfitobacterium, Bacillus, Campylobacter, Vibrionaceae, Xylella, Sulfolobus, Aspergillus, Schizosaccharomyces, Listeria, Neisseria, Mesorhizobium, Ralstonia, Xanthomonas, Candida, Thermobifida and 10 Corynebacterium. Suitably, the lipid acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from one or more of the following organisms: Aeromonas hydrophila, Aeromonas salmonicida, Streptomyces coelicolor, 15 Streptomyces rimosus, Mycobacterium, Streptococcus pyogenes, Lactococcus lactis, Streptococcus pyogenes, Streptococcus thermophilus, Streptomyces thermosacchari, Streptomyces avermitilis Lactobacillus helveticus, Desulfitobacterium dehalogenans, Bacillus sp, Campylobacterjejuni, Vibrionaceae, Xylellafastidiosa, Sulfolobus solfataricus, Saccharomyces cerevisiae, Aspergillus terreus, Schizosaccharomyces 20 pombe, Listeria innocua, Listeria monocytogenes, Neisseria meningitidis, Mesorhizobium loti, Ralstonia solanacearum, Xanthomonas campestris, Xanthomonas axonopodis , Candida parapsilosis Thermobfidafusca and Corynebacterium efficiens. In one aspect, preferably the lipid acyltransferase enzyme according to the present 25 invention is obtainable, preferably obtained, from one or more of Aeromonas hydrophila or Aeromonas salmonicida. In one embodiment suitably the sterol and/or stanol may comprise one or more of the following structural features: 30 i) a 3-beta hydroxy group or a 3-alpha hydroxy group; and/or ii) A:B rings in the cis position or A:B rings in the trans position or C5-C6 is unsaturated.

WO 2006/008508 PCT/GB2005/002823 35 Suitable sterol acyl acceptors include cholesterol and phytosterols, for example alpha sitosterol, beta-sitosterol, stigmasterol, ergosterol, campesterol, 5,6-dihydrosterol, brassicasterol, alpha-spinasterol, beta-spinasterol, gamma-spinasterol, deltaspinasterol, 5 fucosterol, dimosterol, ascosterol, serebisterol, episterol, anasterol, hyposterol, chondrillasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, sterol glycosides, tocopherol, tocotrienol and other natural or synthetic isomeric forms and derivatives. 10 Advantageously, in one embodiment, the sterol acyl acceptor is tocopherol. Suitably the tocopherol may be one or more of gamma, delta, beta or d-alpha tocopherol including d-alpha tocopherol acid succinate for example. In one embodiment, preferably the sterol acyl acceptor is alpha-tocopherol. 15 In one embodiment, preferably the method according to the present invention includes the step of adding tocopherol, preferably alpha-tocopherol, to the oil. In one aspect, preferably the sterol acyl acceptor is cholesterol. 20 In one aspect, preferably the sterol and/or stanol acyl acceptor is a sterol and/or a stanol other than cholesterol. In one aspect of the present invention suitably more than one sterol and/or stanol may act as the acyl acceptor, suitably more than two sterols and/or stanols may act as the 25 acyl acceptor. In other words, in one aspect of the present invention, suitably more than one sterol ester and/or stanol ester may be produced. Suitably, when cholesterol is the acyl acceptor one or more further sterols or one or more stanols may also act as the acyl acceptor. Thus, in one aspect, the present invention provides a method for the in situ production of both a tocopherol ester and at least one other sterol or stanol ester 30 in combination. In other words, the lipid acyltransferase for some aspects of the present invention may transfer an acyl group from a lipid to both tocopherol and at least one further sterol and/or at least one stanol.

WO 2006/008508 PCT/GB20051002823 36 In some aspects, the oil prepared in accordance with the present invention may be used to reduce the risk of cardiovascular diseases. 5 In one aspect, the oil prepared in accordance with the present invention may be used to reduce blood serum cholesterol and/or to reduce low density lipoprotein. Blood serum cholesterol and low density lipoproteins have both been associated with certain diseases in humans, such as atherosclerosis and/or heart disease for example. Thus, it is envisaged that the oils prepared in accordance with the present invention may be 10 used to reduce the risk of such diseases. In another aspect the present invention provides the use of an edible oil according to the present invention for use in the treatment and/or prevention of cardiovascular diseases. 15 Thus, in one aspect the present invention provides the use of an edible oil according to the present invention for use in the treatment and/or prevention of atherosclerosis and/or heart disease. 20 In a further aspect, the present invention provides a medicament comprising an edible oil according to the present invention. In a further aspect, the present invention provides a method of treating and/or preventing a disease in a human or animal patient which method comprising 25 administering to the patient an effective amount of an edible oil according to the present invention. Suitably the sterol acyl acceptor may be one which is naturally found in edible or vegetable oils. 30 Alternatively, or in addition, the sterol acyl acceptor may be one which added to the edible or vegetable oil.

WO 2006/008508 PCT/GB2005/002823 37 When it is the case that a sterol and/or a stanol is added to the edible oil, the sterol and/or stanol may be added before, simultaneously with, and/or after the addition of the lipid acyltransferase according to the present invention. Suitably, the present 5 invention may encompass the addition of exogenous sterols/stanols, particularly phytosterols/phytostanols, to an edible or vegetable oil prior to or simultaneously with the addition of the enzyme according to the present invention. For some aspects, one or more sterols present in the edible oil may be converted to one 10 or more stanols prior to or at the same time as the lipid acyltransferase is added according to the present invention. Any suitable method for converting sterols to stanols may be employed. For example, the conversion may be carried out by chemical hydrogenation for example. The conversion may be conducted prior to the addition of the lipid acyltransferase in accordance with the present invention or simultaneously 15 with the addition of the lipid acyltransferase in accordance with the present invention. Suitably enzymes for the conversion of sterols to stanols are taught in WOOO/061771. Suitably the present invention may be employed to produce phytostanol esters in situ in an edible oil. Phytostanol esters have increased solubility through lipid membranes, 20 bioavailability and enhanced health benefits (see for example W092/99640). An advantage of the present invention is that sterol and/or stanol esters are produced in the edible oil during the degumming thereof. A further advantage is that enzyme is degummed without an increase, or a substantial, increase, in the free fatty acid content 25 of the edible oil. The production of free fatty acids can be detrimental in the edible oil. Preferably, the method according to the present invention results in the degumming of an edible oil wherein the accumulation of free fatty acids is reduced and/or eliminated. Without wishing to be bound by theory, in accordance with the present invention the fatty acid which is removed from the lipid is transferred by the lipid acyltransferase to 30 an acyl acceptor, for example a sterol and/or a stanol. Thus, the overall level of free fatty acids in the foodstuff does not increase or increases only to an insignificant degree. This is in sharp contradistinction to the situation when phospholipases, such as WO 2006/008508 PCT/GB2005/002823 38 Lecitase UltraTM are used in enzymatic degumming of edible oils. In particular, the use of such phospholipases can result in an increased amount of free fatty acid in the edible oil, which can be detrimental. In accordance with the present invention, the accumulation of free fatty acids is reduced and/or eliminated when compared with the amount of free fatty acids 5 which would have been accumulated had a phospholipase A enzyme, such as Lecitase UltraTM, been used in place of the lipid acyltransferase in accordance with the present invention. A lipid acyl transferase according to the present invention may be suitable for use in the enzymatic degumming of vegetable or edible oils. In processing of vegetable or edible oil the 10 edible or vegetable oil is treated with a lipid acyl transferase according to the present invention so as to hydrolyse a major part of the phospholipid. Preferably, the fatty acyl groups are transferred from the polar lipids to an acyl acceptor. The degumming process typically results in the reduction of the content of the polar lipids, particularly of phospholipids, in an edible oil due to hydrolysis of a major part (i.e. more than 50%) of the 15 phospholipid. Typically, the aqueous phase containing the hydrolysed phospholipid is separated from the oil. Suitably, the edible or vegetable oil may initially (pre-treatment with the enzyme according to the present invention) have a phosphorus content of 50-250 ppm. The invention provides a process of enzymatic degumming edible oils, comprising treating the edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of 20 the phospholipid to one or more acyl acceptors, wherein the acyl acceptor is one or more sterol and/or stanol. The invention also provides use of a lipid acyltransferase in the degumming of edible oils to remove phospholipids and to increase the formation of sterol esters and/or stanol esters in the oil. 25 As the skilled person is aware, the term "degumming" as used herein means the refining of oil by converting phosphatides (such as lecithin, phospholipids and occluded oil) into hydratable phosphatides. Oil which has been degummed is more fluid and thus has better handling properties than oil which has not been degummed. The term "transferase" as used herein is interchangeable with the term "lipid 30 acyltransferase". Suitably, the lipid acyltransferase as defined herein catalyses one or more of the following reactions: interesterification, transesterification, alcoholysis, hydrolysis.

WO 2006/008508 PCT/GB2005/002823 39 The term "interesterification" refers to the enzymatic catalysed transfer of acyl groups between a lipid donor and lipid acceptor, wherein the lipid donor is not a free acyl group. 5 The term "transesterification" as used herein means the enzymatic catalysed transfer of an acyl group from a lipid donor (other than a free fatty acid) to an acyl acceptor (other than water). As used herein, the term "alcoholysis" refers to the enzymatic cleavage of a covalent 10 bond of an acid derivative by reaction with an alcohol ROH so that one of the products combines with the H of the alcohol and the other product combines with the OR group of the alcohol. As used herein, the term "alcohol" refers to an alkyl compound containing a hydroxyl 15 group. As used herein, the term "hydrolysis" refers to the enzymatic catalysed transfer of an acyl group from a lipid to the OH group of a water molecule. 20 The term "without increasing or without substantially increasing the free fatty acids" as used herein means that preferably the lipid acyl transferase according to the present invention has 100% transferase activity (i.e. transfers 100% of the acyl groups from an acyl donor onto the acyl acceptor, with no hydrolytic activity); however, the enzyme may transfer less than 100% of the acyl groups present in the lipid acyl donor to the 25 acyl acceptor. In which case, preferably the acyltransferase activity accounts for at least 5%, more preferably at least 10%, more preferably it least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity. 30 The % transferase activity (i.e. the transferase activity as a percentage of the total enzymatic activity) may be determined by the following protocol: WO 2006/008508 PCT/GB2005/002823 40 Enzyme suitable for use in the methods of the invention preferably have phospholipase activity in a standard phospholipase activity assay taught hereinbelow. Determination of phospholipase activity (phospholipase activity assay (PLU-7)): 5 Substrate 0.6% L-a Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 (Sigma X-100) and 5 mM CaC1 2 was dispersed in 0.05M HEPES buffer pH 7. Assay procedure: 10 400 iL substrate was added to a 1.5 mL Eppendorf tube and placed in an Eppendorf Thermomixer at 37*C for 5 minutes. At time t= 0 min, 50 iL enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 1Ox100 rpm in an Eppendorf Thermomixer at 37*C for 10 minutes. At time t=10 min the Eppendorf tube was placed in another thermomixer at 99*C for 10 15 minutes to stop the reaction. Free fatty acid in the samples was analyzed by using the NEFA C kit from WAKO GmbH. Enzyme activity PLU-7 at pH 7 was calculated as micromole fatty acid produced per minute under assay conditions. 20 More preferably the lipid acyl-transferase will also have transferase activity as defined by the protocol below: Protocol for the determination of % acyltransferase activity: 25 An edible bil to which a lipid acyltransferase according to the present invention has been added may be extracted following the enzymatic reaction with CHC13:CH30H 2:1 and the organic phase containing the lipid material is isolated and analysed by GLC and HPLC according to the procedure detailed hereinbelow. From the GLC and 30 HPLC analyses the amount of free fatty acids and one or more of sterol/stanol esters; are determined. A control edible oil to which no enzyme according to the present invention has been added, is analysed in the same way.

WO 2006/008508 PCT/GB2005/002823 41 Calculation: From the results of the GLC and HPLC analyses the increase in free fatty acids and sterollstanol esters can be calculated: A % fatty acid = % Fatty acid(enzyme) - % fatty acid(control); Mv fatty acid 5 average molecular weight of the fatty acids; A = A % sterol ester/Mv sterol ester (where A % sterol ester = % sterol/stanol ester(enzyme) - % sterol/stanol ester(control) and Mv sterol ester average molecular weight of the sterol/stanol esters); 10 The transferase activity is calculated as a percentage of the total enzymatic activity: % transferase activity = A x 100 A+A % fatty acid/(Mv fatty acid) 15 If the free fatty acids are increased in the edible oil they are preferably not increased substantially, i.e. to a significant degree. By this we mean, that the increase in free fatty acid does not adversely affect the quality of the edible oil. The edible oil used for the acyltransferase activity assay is preferably the soya bean oil 20 supplemented with plant sterol (1%) and phosphatidylcholine (2%) oil using the method in Example 3. For the assay the enzyme dosage used is preferably 0.2 PLU-7/g oil, more preferably 0.08 PLU-7/g oil. The level of phospholipid present in the oil and/or the % conversion of sterol is preferably determined after 4 hours, more preferably after 20 hours. 25 In some aspects of the present invention, the term "without substantially increasing free fatty acids" as used herein means that the amount of free fatty acid in a edible oil treated with an lipid acyltransferase according to the present invention is less than the amount of free fatty acid produced in the edible oil when an enzyme other than a lipid 30 acyltransferase according to the present invention had been used, such as for example as compared with the amount of free fatty acid produced when a conventional WO 2006/008508 PCT/GB2005/002823 42 phospholipase enzyme, e.g. Lecitase UltraTm (Novozymes A/S, Denmark), had been used. In addition to, or instead of, assessing the % transferase activity in an oil (above), to 5 identify the lipid acyl transferase enzymes most preferable for use in the methods of the invention the following assay entitled "Protocol for identifying lipid acyltransferases for use in the present invention" can be employed. Protocol for identifying lipid acyltransferases 10 A lipid acyltransferase in accordance with the present invention is on which results in: i) the removal of phospholipid present in a soya bean oil supplemented with plant sterol (1%) and phosphatidylcholine (2%) oil using the method taught in Example 3. 15 and/or ii) the conversion (% conversion) of the added sterol to sterol-ester when using the method taught in Example 3. The GLC method for determining the level of sterol and sterol esters as taught in Example 5 may be used. 20 For the assay the enzyme dosage used may be 0.2 PLU-7/g oil, preferably 0.08 PLU 7/g oil. The level of phospholipid present in the oil and/or the conversion (% conversion) of sterol is preferably determined after 4 hours, more preferably after 20 hours. 25 In the protocol for identifying lipid acyl transferases, after enzymatic treatment, 5% water is preferably added and thoroughly mixed with the oil. The oil is then separated into an oil and water phase using centrifugation (see "Enzyme-catalyzed degumming of vegetable oils" by Buchold, H. and Laurgi A.-G., Fett Wissenschaft Technologie (1993), 95(8), 300-4, ISSN: 0931-5985), and the oil phase can then be analysed for 30 phosphorus content using the following protocol ("Assay for Phosphorus Content"): WO 2006/008508 PCT/GB2005/002823 43 Assay for Phosphorus Content The level of phospholipid present in an oil after degumming is determined by first preparing the oil sample according to the sample preparation taught in the AOAC Official Method 999.10 (>Lead, Cadmium, Zinc, Copper, and Iron in Foods Atomic 5 Absorption Spectrophotometry after Microwave Digestion, First Action 1999 NMKL AOAC Method). The amount of phospholipids in the oil is then measured by analysing the phosphorus content in the oil sample after degumming according to the AOAC Official Method 985.01 (>Metals and Other Elements in Plants and Pet Foods Inductively Coupled Plasma Spectroscopic Method First Action 1985 Final Action 10 1988). The amount of phosphorus present in the oil after degumming is preferably less than 50 ppm, preferably less than 40ppm, preferably less than 30ppm, preferably less than 20ppm, preferably less than 1 Oppm, preferably less than 5ppm. The oil after 15 degumming, as illustrated in the examples may be substantially free of phospholipid, i.e. contain less than lppm phospholipid. The % conversion of the sterol present in the oil is at least 1%, preferably at least 5%, preferably at least 10%, preferably at least 20%, preferably at least 30%, preferably at 20 least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%. In one embodiment the % conversion of the sterol present in the oil is at least 5%, preferably at least 20%. 25 Low Water Degumming It has surprisingly been found that when a lipid acyl transferase is used in a process of enzymatic degumming of an edible oil, the enzymatic degumming can be performed in 30 a very low water environment. Some water may still be required, for example when adding the enzyme to the oil the enzyme may be added in small amount of water, such WO 2006/008508 PCT/GB2005/002823 44 as less than 1%, preferably 0.5%, more preferably less than 0.2%, more preferably less than 1%. Preferably the water content of the edible oil in the processes and uses according to the 5 present invention is less than 1%, preferably less than 0.5%, more preferably less than 0.2%, more preferably less than 0.1%. Thus, one advantage of the present invention is that when only a small amount of water (i.e. <5%, preferably <1%, preferably <0.5%, preferably <0.2%) is used during 10 the enzymatic degumming the gums (i.e. the phosphorus containing portion) separates from the oil, for example in the form of a solid precipitate. The solid precipitate can be readily removed from the degummed oil by methods such as simply decanting the oil or removing or the gum by filtration for example. 15 This contrasts sharply with conventional enzymatic degumming processes in which a significant amount of water is added to the oil. This is because in the conventional enzymatic degumming processes post-degumming because of the high water content, one obtains a water layer which comprises the phosphorus containing portion (for example that portion comprising lysophospholipids). This water lay must be removed 20 and can be removed by centrifugation for example. However, the removal of the water layer is significantly more difficult that the removal of the solid precipitate obtained when using the process of the present invention. Therefore the enzymatic degumming process according to the present invention could 25 be considered as a "low water degumming process". In one embodiment of the present invention, the gum may be removed by adjusting the oil to 5% water followed by centrifugation of the oil. (see "Enzyme-catalyzed degumming of vegetable oils" by Buchold, H. and Laurgi A.-G., Fett Wissenschaft 30 Technologie (1993), 95(8), 300-4).

WO 2006/008508 PCT/GB2005/002823 45 Therefore, the invention provides a process for the degumming of an edible oil, such as a crude edible oil (for example a crude soya oil), without the need for either a prewashing step prior to degumming and/or a step of removing the water added during degumming, which is required when using conventional phospholipases such as 5 pancreatic phospholipase and Lecitase UltraTm. Preferably, the edible oil has a less than a 4.5% water content, more preferably less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%. 10 Suitably, the edible oil may contain at least 0.1% water, such as at least 0.3%, 0.4% or 0.5%. Preferred lipid acyltransferases for use in the present invention are identified as those which have a high activity such as high phospholipid hydrolytic activity or high 15 phospholipid transferase activity on phospholipids in an oil environment, most preferably lipid acyl transferases for use in enzymatic degumming have a high phospholipid to sterol transferase activity. As detailed above, other acyl-transferases suitable for use in the methods of the 20 invention may be identified by identifying the presence of the GDSx, GANDY and HPT blocks either by alignment of the pFam00657 consensus sequence (SEQ ID No 1), and/or alignment to a GDSx acyltransferase, for example SEQ ID No 28. In order to assess their suitability for degumming, i.e. identify those enzymes which have a transferase activity of at least 5%, more preferably at least 10%, more preferably at 25 least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity, such acyltransferases are tested using the "Protocol for the determination of % acyltransferase activity" assay detailed hereinabove. 30 WO 2006/008508 PCT/GB2005/002823 46 The present invention relates to the use of a lipid acyl transferase according to the present invention in degumming edible vegetable oils and/or edible oils and to methods for degumming edible or vegetable oils. 5 In one aspect, the present invention may provide a method comprising using a lipid acyl transferase to remove the non-hydratable phosphorus (NHP) content in oil comprising a relatively high amount of NHP. The term "edible oil" as uses herein may encompass vegetable oils. 10 Preferably, the edible oil prior to treatment in accordance with the present invention comprises a non-hydratable phosphorus content of 50-250ppm, preferably at least 60 ppm, more preferably at least 100 ppm, and even more preferably at least 200 ppm, even more preferably above 250ppm. 15 More preferably, the edible oil prior to treatment in accordance with the present invention comprises a non-hydratable phosphorous content in the range of 60-500 ppm, more preferably in the range of 100-500 ppm, and even more preferably in the range of 200-500 ppm. 20 An edible oil as referred to herein may be any oil having a relatively high amount of a non-hydratable phosphorus, this may include water degumrnmed oil, or more preferably this is a crude-oil or a semi-crude oil. 25 In one aspect, the crude edible oil has, prior to carrying out the method of the invention, a phosphorous content above 350 ppm, more preferably above 400 ppm, even more preferably above 500 ppm, and most preferably above 600 ppm. Oils encompassed by the method according to the present invention may include, but 30 are not limited to, one or more of soya bean oil, canola oil, corn oil, cottonseed oil, palm oil, coconut oil, peanut oil, olive oil, safflower oil, palm kernel oil, rape seed oil and sunflower oil.

WO 2006/008508 PCT/GB2005/002823 47 Preferably, the oil is one or more of soya bean oil, sunflower oil and rape seed oil (sometimes referred to as canola oil). 5 More preferably, the oil is one or more of soya bean oil, sunflower oil or rape seed oil. Most preferably, the oil is soya bean oil. These oils may be. in the form of a crude oil, a semicrude oil, or a water-degummed 10 oil. As used herein, "crude oil" (also referred to herein as a non-degummed oil) may be a pressed or extracted oil or a mixture thereof from e.g. rapeseed, soybean, or sunflower. The phosphatide content in a crude oil may vary from 0.5-3% w/w corresponding 15 to a phosphorus content in the range of 200-1200 ppm, more preferably in the range of 250-1200 ppm. Apart from the phosphatides the crude oil also contains small concentrations of carbohydrates, sugar compounds and metal/phosphatide acid complexes of Ca, Mg and Fe. 20 As used herein, "semicrude oil" refers to any oil which is not a crude oil, but which has a phosphatide content above 250 ppm, more preferably above 500 ppm. Such an oil could e.g. be obtained by subjecting a crude oil to a process similar to the "water degumming" process described below. 25 As used herein, "water-degummed oil" may be typically be obtained by a "water degumming process" comprising mixing 1-3% w/w of hot water with warm (60-90*C) crude oil. Usual treatment periods are 30-60 minutes. The water-degumming step removes the phosphatides and mucilaginous gums which become insoluble in the oil when hydrated. The hydrated phosphatides and gums can be separated from the oil by 30 settling, filtration or centrifugation - centrifugation being the more prevalent practice. The essential object in said water-degumming process is to separate the hydrated phosphatides from the oil. The mixing of hot water into the oil, described above, WO 2006/008508 PCT/GB20051002823 48 should herein be understood broadly as mixing of an aqueous solution into the oil according to standard water-degumming procedures in the art. Advantageously, the method and uses of the present invention enable degumming of 5 edible oils in a low water (<5%, preferably less than 2%, more preferably less than 1%) environments. Therefore degumming can be performed with adding less water than when using conventional enzymes. A further advantage of the present invention is the production of sterol esters (in particular tocopherol esters) in the oil. A yet further advantage of the present invention is removal (preferably complete removal) of 10 phospholipids. A further advantage of the present invention is the removal (preferably complete removal) of phospholipids without removal of phytosterol, and in particular tocopherol. It is preferred that, due to the esterification of the phytosterol, there is no significant removal of phytosterols such as tocopherol from the oil instead they are simply esterified. However, in one embodiment the amount of phytosterol such as 15 tocopherol may be reduced. In such embodiments the absolute levels of phytosterol such as tocopherol may be reduced by preferably no more than 10%, alternatively no more than 25%, alternatively no more than 50%, alternatively no more than 75%. A yet further advantage of the present invention is the removal (preferably complete removal) of phospholipids without hydrolysis of triglycerides. 20 For the ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section. 25 DEFINITION OF SETS Amino acid set 1: Amino acid set 1 30 Glv8, Asp9. Serl0, Leul1, Ser12, Tyr15, Gly44, Asp45, Thr46, Glu69, Leu70, Gly7l, Gly72, Asn73. Asp74, Gly75, Leu76, Gln106, Ile107, Arg108, LeuI09, Prol 10, WO 2006/008508 PCT/GB2005/002823 49 Tyr113, Phel2l, Phel39, Phel4O, Metl4l, Tyrl45, Met151, Aspl54 His157 Gly155, Ilel56, Pro158 The highly conserved motifs, such as GDSx and catalytic residues, were deselected 5 from set I (residues underlined). For the avoidance of doubt, set I defines the amino acid residues within 1 OA of the central carbon atom of a glycerol in the active site of the 1 IVN model. Amino acid set 2: 10 Amino acid set 2 (note that the numbering of the amino acids refers to the amino acids in the P10480 mature sequence) LeuI7, Lys22, Met23, Gly4O, Asn8O, Pro8l, Lys82, Asn87, Asn88, Trp1 11, Va1l 12, Alal14, Tyr117, Leu118, Prol56, Glyl59, Gln160, Asnl6l, Prol62, Ser163, Alal64, 15 Arg165, Ser166, Gln167, Lys168, Vall69, Val170, Glul7l, Ala172, Tyr179, Hisl80, Asn181, Met209, Leu2I0, Arg211, Asn215, Lys284, Met285, Gln289 and Val290. Table of selected residues in Set I compared with Set 2: IVN model P10480 Mature sequence Residue IVN A.hyd homologue Number PFAM Structure Gly8 Gly32 Asp9 Asp33 SerlO Ser34 Leul1 Leu35 Leul7 Ser12 Ser36 Ser18 Lys22 Met23 TyrI5 Gly58 Gly4O WO 2006/008508 PCT/GB2005/002823 50 Gly44 Asn98 Asn8O Asp45 Pro99 Pro8l Thr46 LysIQO Lys82 Asn87 AsnSS Glu69 Trp129 Trpl I LeU7O Vall30 Val 112 Gly71 Gly13l Gly72 Ala132 Alall14 Asn73 Asnl33 Asp74 Asp 134 Gly75 Tyr135 TyrlI17 Leu76 Leul36 Leull8 Gln106 Pro174 Pro156 BOW10 Gly177 Glyl 59 ArglOS Glnl78 Glnl6O Leu1O9 Asnl 79 Asnl 61 ProllO 180 to 190 Pro162 Tyrll13 Serl 63 Alal 64 Arg165 Ser166 Gln167 Lys168 Val 169 Va1170 Glu 171 Alal 72 Phel2l His198 Tyr197 Tyr179 His198 Hisl 80 Asn199 Asni~i WO 2006/008508 PCT/GB2005/002823 51 Phe139 Met227 Met2O9 Phel40 Leu228 Leu2lO Metl4l Arg229 Arg2ll Tyr145 Asn233 Asn215 Lys284 Met151 Met303 Met285 Asp154 Asp306 Gly155 Gln307 Gln289 Ile156 Va1308 Va1290 Hisl57 His309 Prol58 Pro310 Amino acid set 3: 5 Amino acid set 3 is identical to set 2 but refers to the Aeromonas salmonicida (SEQ ID No. 28) coding sequence, i.e. the amino acid residue numbers are 18 higher in set 3 as this reflects the difference between the amino acid numbering in the mature protein (SEQ ID No. 2) compared with the protein including a signal sequence (SEQ ID No. 28). 10 The mature proteins of Aeromonas salmonicida GDSX (SEQ ID No. 28) and Aeromonas hydrophila GDSX (SEQ ID No. 26) differ in five amino acids. These are Thr3Ser, Gln182Lys, Glu309Ala, Ser3 I OAsn, Gly318-, where the salmonicida residue is listed first and the hydrophila residue is listed last (FIGURE 59). The hydrophila 15 protein is only 317 amino acids long and lacks a residue in position 318. The Aeromonas salmonicidae GDSX has considerably high activity on polar lipids such as galactolipid substrates than the Aeromonas hydrophila protein. Site scanning was performed on all five amino acid positions. 20 WO 2006/008508 PCT/GB20051002823 52 Amino acid set 4: Amino acid set 4 is S3, Q182, E309, S310, and -318. 5 Amino acid set 5: F13S, D15N, S18G, S18V, Y30F, D116N, DI16E, D157 N, Y226F, D228N Y230F. Amino acid set 6: 10 Amino acid set 6 is Ser3, Leul7, Lys22, Met23, Gly4O, Asn80, Pro81, Lys82, Asn 87, Asn88, Trplll,Va112,Ala114,Tyrll 7 , Leu118, Prol56,Gly159,Glnl6O,Asnl161, Prol62, Ser163, Ala164, Arg165, Ser166, G1n167, Lys168, Va1169, Val170, Glul71, Ala172, Tyr179, His180, Asn181, G1n182, Met209, Leu2lO, Arg2l 1, Asn215, 15 Lys284, Met285, Gln289, Va1290, Glu309, Ser310, -318. The numbering of the amino acids in set 6 refers to the amino acids residues in P10480 (SEQ ID No. 2) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P 10480 and/or 20 IVN. Amino acid set 7: Amino acid set 7 is Ser3, Leul7, Lys22, Met23, Gly4O, Asn8O, Pro8l, Lys82, Asn 87, 25 Asn88, Trplll, Val112, Alall4, Tyr117, Leu118, Prol56, Gly159, Glnl60, Asnl6l, Prol62, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Va1169, Va1170, Glul7l, Ala172, Tyr179, His1SO, Asn181, Gln182, Met209, Leu21O, Arg2ll, Asn215, Lys284, Met285, Gin289, Val290, Glu309, Ser310, -318, Y30X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), Y226X (where X is 30 selected from A, C, D, E, G, H, 1, K, L, M, N, P, Q, R, S, T, V, or W), Y230X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), S18X WO 2006/008508 PCT/GB2005/002823 53 (where X is selected from A, C, D, E, F, H, I, K, L, M, N, P, Q, R, T, W or Y), D157X (where X is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y). The numbering of the amino acids in set 7 refers to the amino acids residues in P10480 5 (SEQ ID No. 2) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1IVN). ISOLATED 10 In one aspect, preferably the polypeptide or protein for use in the present invention is in an isolated form. The term "isolated" means that the sequence is at least substantially free from at least one other component with which the sequence is naturally associated in nature and as found in nature. 15 PURIFIED In one aspect, preferably the polypeptide or protein for use in the present invention is in a purified form. The term "purified" means that the sequence is in a relatively pure 20 state - e.g. at least about 51% pure, or at least about 75%, or at least about 80%, or at least about 90% pure, or at least about 95% pure or at least about 98% pure. CLONING A NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE ACCORDING TO THE PRESENT INVENTION 25 A nucleotide sequence encoding either a polypeptide which has the specific properties as defined herein or a polypeptide which is suitable for modification may be isolated from any cell or organism producing said polypeptide. Various methods are well known within the art for the isolation of nucleotide sequences. 30 WO 2006/008508 PCT/GB20051002823 54 For example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the polypeptide. If the amino acid sequence of the polypeptide is known, labelled oligonucleotide probes may be synthesised and used to identify polypeptide-encoding clones from the 5 genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known polypeptide gene could be used to identify polypeptide-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used. 10 Alternatively, polypeptide-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing an enzyme inhibited by the polypeptide, thereby allowing clones expressing the polypeptide to be identified. 15 In a yet further alternative, the nucleotide sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. et al (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes et al (1984) EMBO J. 3, p 801-805. In the 20 phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors. The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating 25 fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K et al (Science (1988) 239, pp 487-491). 30 WO 2006/008508 PCT/GB2005/002823 55 NUCLEOTIDE SEQUENCES The present invention also encompasses nucleotide sequences encoding polypeptides having the specific properties as defined herein. The term "nucleotide sequence" as used 5 herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double stranded or single-stranded whether representing the sense or antisense strand. 10 The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence. In a preferred embodiment, the nucleotide sequence per se encoding a polypeptide having 15 the specific properties as defined herein does not cover the native nucleotide sequence in its natural environment when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence". In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native 20 environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. Thus, the polypeptide of the present invention can be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism. 25 Preferably the polypeptide is not a native polypeptide. In this regard, the term "native polypeptide" means an entire polypeptide that is in its native environment and when it has been expressed by its native nucleotide sequence. 30 Typically, the nucleotide sequence encoding polypeptides having the specific properties as defined herein is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the WO 2006/008508 PCT/GB2005/002823 56 nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al (1980) Nuc Acids Res Symp Ser 225-232). 5 MOLECULAR EVOLUTION Once an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the 10 sequence in order to prepare an enzyme in accordance with the present invention. Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites. 15 A suitable method is disclosed in Morinaga et al (Biotechnology (1984) 2, p6 4 6- 64 9 ). Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long (Analytical Biochemistry (1989), 180, p 147-151). Instead of site directed mutagenesis, such as described above, one can introduce 20 mutations randomly for instance using a commercial kit such as the GeneMorph PCR mutagenesis kit from Stratagene, or the Diversify PCR random mutagenesis kit from Clontech. EP 0 583 265 refers to methods of optimising PCR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those described in EP 0 866 796. Error prone PCR technologies are suitable for the 25 production of variants of lipid acyl transferases with preferred characteristics. W00206457 refers to molecular evolution of lipases. A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as 30 Dnase I, and reassembling full nucleotide sequences coding for functional proteins. Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence. DNA WO 2006/008508 PCT/GB2005/002823 57 shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. Suitable methods for performing 'shuffling' can be found in EPO 752 008, EP1 138 763, EP1 103 606. Shuffling can also be combined with other forms of DNA mutagenesis as described in 5 US 6,180,406 and WO 01/34835. Thus, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either in vivo or in vitro, and to subsequently screen for improved functionality of the encoded polypeptide by various means. Using in silico and exo 10 mediated recombination methods (see WO 00/58517, US 6,344,328, US 6,361,974), for example, molecular evolution can be performed where the variant produced retains very low homology to known enzymes or proteins. Such variants thereby obtained may have significant structural analogy to known transferase enzymes, but have very low amino acid sequence homology. 15 As a non-limiting example, in addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide. 20 The application of the above-mentioned and similar molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial 25 mutations or variants. There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host cell or in vitro, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability, 30 altered enzymatic activity/specificity in preferred environmental conditions, e.g. temperature, pH, and/or substrate.

WO 2006/008508 PCT/GB2005/002823 58 As will be apparent to a person skilled in the art, using molecular evolution tools an enzyme may be altered to improve the functionality of the enzyme. Suitably, the lipid acyltransferase used in the invention may be a variant, i.e. may 5 contain at least one amino acid substitution, deletion or addition, when compared to a parental enzyme. Variant enzymes retain at least 1%, 2%, 3%, 5%, 10%, 15%, 20%, 30%, 40%, 50 %, 60%, 70%, 80%, 90%, 95%, 97%, 99% homology with the parent enzyme. Suitable parent enzymes may include any enzyme with esterase or lipase activity. Preferably, the parent enzyme aligns to the pfam00657 consensus sequence. 10 In a preferable embodiment a variant lipid acyltransferase enzyme retains or incorporates at least one or more of the pfam00657 consensus sequence amino acid residues found in the GDSx, GANDY and HPT blocks. 15 Enzymes, such as lipases with no or low lipid acyltransferase activity in an aqueous environment may be mutated using molecular evolution tools to introduce or enhance the transferase activity, thereby producing a lipid acyltransferase enzyme with significant transferase activity suitable for use in the compositions and methods of the present invention. 20 Suitably, the lipid acyltransferase for use in the invention may be a variant with enhanced enzyme activity phospholipids when compared to the parent enzyme. Preferably, such variants also have low or no activity on lyso polar lipids. The enhanced activity on phospholipids may be the result of hydrolysis and/or transferase 25 activity or a combination of both. Variant lipid acyltransferases for use in the invention may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides compared with the parent enzyme. 30 Suitably t1ie variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides.

WO 2006/008508 PCT/GB2005/002823 59 Alternatively, the variant enzyme for use in the invention may have increased activity on triglycerides, and/or may also have increased activity on one or more of the following, polar lipids, phospholipids, lecithin, phosphatidylcholine. 5 Variants of lipid acyltransferases are known, and one or more of such variants may be suitable for use in the methods and uses according to the present invention and/or in the enzyme compositions according to the present invention. By way of example only, variants of lipid acyltransferases are described in the following references may be used 10 in accordance with the present invention: Hilton & Buckley J Biol. Chem. 1991 Jan 15: 266 (2): 997-1000; Robertson et al J. Biol. Chem. 1994 Jan 21; 269(3):2146-50; Brumlik et al J. Bacteriol 1996 Apr; 178 (7): 2060-4; Peelman et al Protein Sci. 1998 Mar; 7(3):587-99. 15 AMINO ACID SEQUENCES The present invention also encompasses amino acid sequences of polypeptides having the specific properties as defined herein. 20 As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide". The amino acid sequence may be prepared/isolated from a suitable source, or it may be 25 made synthetically or it may be prepared by use of recombinant DNA techniques. Suitably, the amino acid sequences may be obtained from the isolated polypeptides taught herein by standard techniques. 30 One suitable method for determining amino acid sequences from isolated polypeptides is as follows: WO 2006/008508 PCT/GB2005/002823 60 Purified polypeptide may be freeze-dried and 100 pg of the freeze-dried material may be dissolved in 50 pl of a mixture of 8 M urea and 0.4 M ammonium hydrogen carbonate, pH 8.4. The dissolved protein may be denatured and reduced for 15 minutes at 50*C following overlay with nitrogen and addition of 5 pl of 45 mM dithiothreitol. 5 After cooling to room temperature, 5 pl of 100 mM iodoacetamide may be added for the cysteine residues to be derivatized for 15 minutes at room temperature in the dark under nitrogen. 135 pl of water and 5 pg of endoproteinase Lys-C in 5 pl of water may be added to the 10 above reaction mixture and the digestion may be carried out at 37"C under nitrogen for 24 hours. The resulting peptides may be separated by reverse phase HPLC on a VYDAC C 18 column (0.46x15cm;10pm; The Separation Group, California, USA) using solvent A: 15 0.1% TFA in water and solvent B: 0.1% TFA in acetonitrile. Selected peptides may be re-chromatographed on a Develosil C1 8 column using the same solvent system, prior to N-terminal sequencing. Sequencing may be done using an Applied Biosystems 476A sequencer using pulsed liquid fast cycles according to the manufacturer's instructions (Applied Biosystems, California, USA). 20 SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY The present invention also encompasses the use of sequences having a degree of 25 sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)"). Here, the term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can 30 be equated with "identity".

WO 2006/008508 PCT/GB2005/002823 61 The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme. 5 In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical 10 properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% 15 identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express 20 homology in terms of sequence identity. Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. 25 % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments 30 are performed only over a relatively short number of residues.

WO 2006/008508 PCT/GB2005/002823 62 Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is 5 performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology. 10 However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a 15 gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG 20 Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension. Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer 25 program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux et al 1984 Nuc. Acids Research 12 p387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al1999 Short Protocols in Molecular Biology, 4* Ed - Chapter 18), FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and the GENEWORKS suite of 30 comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called WO 2006/008508 PCT/GB2005/002823 63 BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov). 5 Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the 10 BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62. 15 Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASISTM (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244). 20 Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result. In a preferable aspect of the present invention the following software and settings for 25 calculating percentage homology/identity are used. For amino acid sequences percentage of identities (homology) or "positives" are calculated by the AlignX VectorNTI (Vector NTI Advance 9.1 from Invitrogen Corporation, Carlsbad, California, USA.), for each possible pair of amino acid sequences Settings are default parameters (Gap opening penalty - 10, Gap extension penalty 0.1). 30 The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent WO 2006/008508 PCT/GB2005/002823 64 substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and 5 glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine. 10 Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other: ALIPHATIC Non-polar G A P ILV Polar - uncharged C S T M N Q Polar - charged D E KR AROMATIC HFWY 15 The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution 20 may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as 0), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

WO 2006/008508 PCT/GB2005/002823 65 Replacements may also be made by unnatural amino acids. Variant amino acid sequences may include suitable spacer groups that may be inserted 5 between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or p alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid 10 residues wherein the a-carbon substituent group is on the residue's nitrogen atom rather than the a-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134. 15 Nucleotide sequences for use in the present invention or encoding a polypeptide having the specific properties defined herein may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends 20 of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences. 25 The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences discussed herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc. 30 Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways.

WO 2006/008508 PCT/GB2005/002823 66 Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other virallbacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may 5 be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of 10 medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention. Variants and strain/species homologues may also be obtained using degenerate PCR 15 which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp 20 program is widely used. The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences. 25 Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes maybe desired 30 in order to introduce restriction polypeptide recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

WO 2006/008508 PCT/GB2005/002823 67 Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other 5 fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein. Polynucleotides such as DNA polynucleotides and probes according to the invention may 10 be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques 15 for accomplishing this using automated techniques are readily available in the art. Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid 20 targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable 25 restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector. HYBRIDISATION The present invention also encompasses sequences that are complementary to the 30 sequences of the present invention or sequences that are capable of hybridising either WO 2006/008508 PCT/GB2005/002823 68 to the sequences of the present invention or to sequences that are complementary thereto. The term "hybridisation" as used herein shall include "the process by which a strand of 5 nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies. The present invention also encompasses the use of nucleotide sequences that are 10 capable of hybridising to the sequences that are complementary to the subject sequences discussed herein, or any derivative, fragment or derivative thereof. The present invention also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences discussed herein. 15 Hybridisation conditions are based on the melting temperature (Tm) of the nucleotide binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below. 20 Maximum stringency typically occurs at about Tm-5*C (5*C below the Tm of the probe); high stringency at about 5*C to 10*C below Tm; intermediate stringency at about 10*C to 20*C below Tm; and low stringency at about 20*C to 25*C below Tm. As will be understood by those of skill in the art, a maximum stringency hybridisation 25 can be used to identify or detect identical nucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences. Preferably, the present invention encompasses sequences that are complementary to 30 sequences that are capable of hybridising under high stringency conditions or intermediate stringency conditions to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

WO 2006/008508 PCT/GB2005/002823 69 More preferably, the present invention encompasses sequences that are complementary to sequences that are capable of hybridising under high stringent conditions (e.g. 65*C and 0.IxSSC {IxSSC = 0.15 M NaCl, 0.015 M Na-citrate pH 7.0}) to nucleotide 5 sequences encoding polypeptides having the specific properties as defined herein. The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein). 10 The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein). 15 Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences discussed herein under conditions of intermediate to maximal stringency. In a preferred aspect, the present invention covers nucleotide sequences that can 20 hybridise to the nucleotide sequences discussed herein, or the complement thereof, under stringent conditions (e.g. 50*C and 0.2xSSC). In a more preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, 25 under high stringent conditions (e.g. 65*C and 0.IxSSC). EXPRESSION OF POLYPEPTIDES A nucleotide sequence for use in the present invention or for encoding a polypeptide 30 having the specific properties as defined herein can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in polypeptide form, in and/or from a compatible host cell. Expression may WO 2006/008508 PCT/GB2005/002823 70 be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two 5 or more different promoters described above. The polypeptide produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal 10 sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane. EXPRESSION VECTOR 15 The term "expression vector" means a construct capable of in vivo or in vitro expression. Preferably, the expression vector is incorporated in the genome of the organism. The term "incorporated" preferably covers stable incorporation into the genome. 20 The nucleotide sequence of the present invention or coding for a polypeptide having the specific properties as defined herein may be present in a vector, in which the nucleotide sequence is operably linked to regulatory sequences such that the regulatory sequences are capable of providing the expression of the nucleotide sequence by a suitable host organism, i.e. the vector is an expression vector. 25 The vectors of the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide having the specific properties as defined herein. 30 The choice of vector, e.g. plasmid, cosmid, virus or phage vector, will often depend on the host cell into which it is to be introduced.

WO 2006/008508 PCT/GB2005/002823 71 The vectors may contain one or more selectable marker genes - such as a gene which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Alternatively, the selection may be accomplished by co-transformation (as 5 described in W091/17243). Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell. 10 Thus, in a further embodiment, the invention provides a method of making nucleotide sequences of the present invention or nucleotide sequences encoding polypeptides having the specific properties as defined herein by introducing a nucleotide sequence into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. 15 The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUBI 10, pE194, pAMB1 and pU702. 20 REGULATORY SEQUENCES In some applications, a nucleotide sequence for use in the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein may be operably linked to a regulatory sequence which is capable of providing 25 for the expression of the nucleotide sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector. 30 The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way WO 2006/008508 PCT/GB2005/002823 72 that expression of the coding sequence is achieved under conditions compatible with the control sequences. The term "regulatory sequences" includes promoters and enhancers and other 5 expression regulation signals. The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site. 10 Enhanced expression of the nucleotide sequence encoding the enzyme having the specific properties as defined herein may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions. 15 Preferably, the nucleotide sequence of the present invention may be operably linked to at least a promoter. Examples of suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art. 20 CONSTRUCTS The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes a nucleotide sequence encoding a polypeptide having the specific properties as defined herein for use according to the present invention directly or 25 indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Shl-intron or the ADH intron, intennediate the promoter and the nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural 30 combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

WO 2006/008508 PCT/GB2005/002823 73 The construct may even contain or express a marker which allows for the selection of the genetic construct. 5 For some applications, preferably the construct comprises at least a nucleotide sequence of the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein operably linked to a promoter. HOST CELLS 10 The term "host cell" - in relation to the present invention includes any cell that comprises either a nucleotide sequence encoding a polypeptide having the specific properties as defined herein or an expression vector as described above and which is used in the recombinant production of a polypeptide having the specific properties as 15 defined herein. Thus, a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence of the present invention or a nucleotide sequence that expresses a polypeptide having the specific properties as defined herein. 20 The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells. Preferably, the host cells are not human cells. Examples of suitable bacterial host organisms are gram negative bacterium or gram 25 positive bacteria. Depending on the nature of the nucleotide sequence encoding a polypeptide having the specific properties as defined herein, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred. 30 In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or WO 2006/008508 PCT/GB2005/002823 74 in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected. The use of suitable host cells, such as yeast, fungal and plant host cells - may provide 5 for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention. 10 The host cell may be a protease deficient or protease minus strain. ORGANISM The term "organism" in relation to the present invention includes any organism that 15 could comprise a nucleotide sequence according to the present invention or a nucleotide sequence encoding for a polypeptide having the specific properties as defined herein and/or products obtained therefrom. Suitable organisms may include a prokaryote, fungus, yeast or a plant. 20 The term "transgenic organism" in relation to the present invention includes any organism that comprises a nucleotide sequence coding for a polypeptide having the specific properties as defined herein and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence coding for a 25 polypeptide having the specific properties as defined herein within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism. The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter 30 which is also in its natural environment.

WO 2006/008508 PCT/GB2005/002823 75 Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, a nucleotide sequence coding for a polypeptide having the specific properties as defined herein, constructs as defined herein, vectors as defined herein, plasmids as defined herein, cells as defined herein, or 5 the products thereof. For example the transgenic organism can also comprise a nucleotide sequence coding for a polypeptide having the specific properties as defined herein under the control of a heterologous promoter. TRANSFORMATION OF HOST CELLS/ORGANISM 10 As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include E. coli and Bacillus subtilis. In one embodiment the host cell is a bacteria, preferably a gram-positive bacteria, 15 preferably a host cell selected from Actinobacteria, such as Biofidobacteria and Aeromonas, particularly preferably Aeromonas salmonicida. Still more preferred are Actinomicetales such as Corynebacteria, in particular Corynebacterium glutamicum and Nocardia. Particularly preferred are Streptomycetaceae, such as Streptomyces, especially S. lividans. 20 A microbial host can be used for expression of the galactolipase gene, e.g. Eubacteria, Archea or Fungi, including yeast. Preferred are Eubacteria, for example, Firmicutes (low GC-Gram positive bacteria), such as Bacillus subtilis and other bacillus species, lactic acid bacteria such as species of genera Lactobacillus and Lactococcus. 25 Also preferred are Gram-negative Proteobacteria, in particular Gammaproteobacteria, such as host species belonging to the genera Pseudomonas, Xanthomonas, Citrobacter and Escherichia, especially Escherichia coli. 30 Preferably the host species is a Gram positive expression host such as Aeromonas salmonicida, Streptomyces lividans or Corynebacterium glutamicum as detailed in GB application number 0513859.9 WO 2006/008508 PCT/GB2005/002823 76 In another embodiment the host cell is the same genus as the native host species, i.e. the recombinant gene is re-introduced and expressed in a species from the same genus as the species from which the recombinant gene was isolated. 5 In another embodiment the host cell is the native host species, i.e. the recombinant gene is re-introduced and expressed in the same species from which the recombinant gene was isolated. 10 Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as 15 by removal of introns. In another embodiment the transgenic organism can be a yeast. Filamentous fungi cells may be transformed using various methods known in the art 20 such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of Aspergillus as a host microorganism is described in EP 0 238 023. Another host organism can be a plant. A review of the general techniques used for 25 transforming plants may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol (1991) 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375. 30 General teachings on the transformation of fungi, yeasts and plants are presented in following sections.

WO 2006/008508 PCT/GB2005/002823 77 TRANSFORMED FUNGUS A host organism may be a fungus - such as a filamentous fungus. Examples of suitable such hosts include any member belonging to the genera Thermomyces, Acremonium, 5 Aspergillus, Penicillium, Mucor, Neurospora, Trichoderma and the like. Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filarnentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to N. 10 crassa is found, for example in Davis and de Serres, Methods Enzymol (1971) 17A: 79-143. Further teachings on transforming filamentous fungi are reviewed in US-A-5674707. 15 In one aspect, the host organism can be of the genus Aspergillus, such as Aspergillus niger. A transgenic Aspergillus according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic 20 manipulation. In: Martinelli S.D., Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666). Gene expression in filamentous fungi has been reviewed in Punt et al. (2002) Trends Biotechnol 2002 May;20(5):200- 6 , Archer & Peberdy Crit Rev Biotechnol (1997) 25 17(4):273-306. TRANSFORMED YEAST 30 In another embodiment, the transgenic organism can be a yeast.

WO 2006/008508 PCT/GB2005/002823 78 A review of the principles of heterologous gene expression in yeast are provided in, for example, Methods Mol Biol (1995), 49:341-54, and Curr Opin Biotechnol (1997) Oct;8(5):554-60 5 In this regard, yeast - such as the species Saccharomyces cerevisi or Pichiapastoris (see FEMS Microbiol Rev (2000 24(1):45-66), may be used as a vehicle for heterologous gene expression. A review of the principles of heterologous gene expression in Saccharomyces cerevisiae 10 and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.). For the transformation of yeast, several transformation protocols have been developed. 15 For example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen et al., (1978, Proceedings ofthe National Academy ofSciences ofthe USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168). 20 The transformed yeast cells may be selected using various selective markers - such as auxotrophic markers dominant antibiotic resistance markers. A suitable yeast host organism can be selected from the biotechnologically relevant yeasts species such as, but not limited to, yeast species selected from Pichi'a spp., 25 Hansenula spp., Kluyveromyces, Yarrowinia spp., Saccharomyces spp., including S. cerevisiae, or Schizosaccharomyce spp. including Schizosaccharomyce pombe. A strain of the methylotrophic yeast species Pichia pastoris may be used as the host organism. 30 In one embodiment, the host organism may be a Hansenula species, such as H. polymorpha (as described in WO01/39544).

WO 2006/008508 PCT/GB2005/002823 79 TRANSFORMED PLANTS/PLANT CELLS A host organism suitable for the present invention may be a plant. A review of the 5 general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant MolBiol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27), or in WOO1/16308. SECRETION 10 Often, it is desirable for the polypeptide to be secreted from the expression host into the culture medium from where the enzyme may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the 15 context of the present invention. Typical examples of heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA - both 18 and 24 amino acid versions e.g. from Aspergillus), the a-factor gene (yeasts e.g. Saccharomyces, 20 Kluyveromyces and Hansenula) or the a-amylase gene (Bacillus). DETECTION A variety of protocols for detecting and measuring the expression of the amino acid 25 sequence are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting faces) . A wide variety of labels and conjugation techniques are known by those skilled in the 30 art and can be used in various nucleic and amino acid assays.

WO 2006/008508 PCT/GB2005/002823 80 A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures. 5 Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A 4,277,437; US-A-4,275,149 and US-A-4,366,241. 10 Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567. FUSION PROTEINS 15 A polypeptide having the specific properties as defined herein may be produced as a fusion protein, for example to aid in extraction and purification thereof. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GALA (DNA binding and/or transcriptional activation domains) and p-galactosidase. It may also be 20 convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the protein sequence. Gene fusion expression systems in E. coli have been reviewed in Curr. Opin. 25 Biotechnol. (1995) 6(5):501-6. In another embodiment of the invention, the amino acid sequence of a polypeptide having the specific properties as defined herein may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for 30 agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.

WO 2006/008508 PCT/GB2005/002823 81 The invention will now be described, by way of example only, with reference to the following figures and examples. 5 Figure 1 shows the profile of the lipid acyltransferase activity (PNP-caprylate assay) obtained after anion exchange chromatography (IEC); Figure 2 shows the results of SDS-PAGE analyses of purified the lipid acyltransferase fractions (4-12% Mes, +DTT, 40/10 1d sample was applied to the gel): 10 Lane 1. Lipid acyltransferase sample after desalting, 40 d was applied to the gel Lane 2. Lipid acyltransferase sample after desalting, 10 ptl was applied to the gel Lane 3. Purified Lipid acyltransferase lipase after IEC (pool 27-39), 40 pl was applied to the gel Lane 4. Purified Lipid acyltransferase lipase after IEC (pool 27-39, 10 p1 was applied 15 to the gel; Figure 3 shows a TLC (Solvent 4) of reaction products from the lipid acyltransferase treatment of soya bean oil samples according to Table 2. As a reference phosphatidylcholine (PC) was also analysed; 20 Figure 4 shows a TLC (Solvent 1) of reaction products from the lipid acyltransferase treatment of soya bean oil samples according to Table 2. As reference free fatty acid (FFA) and Mono-di-triglyceride (TRI/DI/MONO) were also analysed; 25 Figure 5 shows a TLC (Solvent 5) of reaction products from the lipid acyltransferase treatment of soya bean oil samples according to Table 2. As reference Cholesterol (CHL) and Cholesterolester (CHL-ester) were also analysed; Figure 6 shows a TLC (Solvent 4) of reaction products from the lipid acyltransferase 30 or Lecitase UltraTm treatment of soya bean oil samples according to Table 3 for 20 hours; WO 2006/008508 PCT/GB2005/002823 82 Figure 7 shows a TLC (Solvent 5) of reaction products from the lipid acyltransferase or Lecitase UltraTm treatment of soya bean oil samples according to Table 3 for 20 hours. Cholesterol ester (CHL ester); Mono-di-Triglyceride(MONO/DI/1'RI) and 5 plant sterol were also analysed as references. Identification of free fatty acid (FFA) is also indicated; Figure 8 shows a TLC (Solvent 4) of reaction products from the lipid acyltransferase or Lecitase UltraTm treatment of soya bean oil samples according to Table 3 for 4 10 hours; Figure 9 shows a TLC (Solvent 5) of reaction products from the lipid acyltransferase or Lecitase UltraTM treatment of soya bean oil samples according to Table 3 for 4 hours. Cholesterol ester (CHL ester); Mono-di-Triglyceride (MONO/DIITRI) and 15 plant sterol were also analysed as references. Identification of free fatty acid (FFA) is also indicated; Figure 10 shows the amino acid sequence of a mutant Aeromonas salmonicida mature lipid acyltransferase (GCAT) with a mutation of Asn8OAsp (notably, amino acid 80 is 20 in the mature sequence); Figure 11 shows an amino acid sequence (SEQ ID No. 1) a lipid acyl transferase from Aeromonas hydrophila (ATCC #7965); 25 Figure 12 shows a pfam00657 consensus sequence from database version 6 (SEQ ID No. 2); Figure 13 shows an amino acid sequence (SEQ ID No. 3) obtained from the organism Aeromonas hydrophila (P 10480; GI: 121051); 30 Figure 14 shows an amino acid sequence (SEQ ID No. 4) obtained from the organism Aeromonas salmonicida (AAG098404; GI:9964017); WO 2006/008508 PCT/GB2005/002823 83 Figure 15 shows an amino acid sequence (SEQ ID No. 5) obtained from the organism Streptomyces coelicolor A3(2) (Genbank accession number NP_631558); 5 Figure 16 shows an amino acid sequence (SEQ ID No. 6) obtained from the organism Streptomyces coelicolor A3(2) (Genbank accession number: CAC42140); Figure 17 shows an amino acid sequence (SEQ ID No. 7) obtained from the organism Saccharomyces cerevisiae (Genbank accession number P41734); 10 Figure 18 shows an amino acid sequence (SEQ ID No. 8) obtained from the organism Ralstonia (Genbank accession number: AL646052); Figure 19 shows SEQ ID No. 9. Scoel NCBI protein accession code CAB39707.1 15 GI:4539178 conserved hypothetical protein [Streptomyces coelicolor A3(2)]; Figure 20 shows an amino acid shown as SEQ ID No. 10. Scoe2 NCBI protein accession code CAC01477.1 GI:9716139 conserved hypothetical protein [Streptomyces coelicolor A3(2)]; 20 Figure 21 shows an amino acid sequence (SEQ ID No. 11) Scoe3 NCBI protein accession code CAB88833.1 GI:7635996 putative secreted protein. [Streptomyces coelicolor A3(2)]; 25 Figure 22 shows an amino acid sequence (SEQ ID No. 12) Scoe4 NCBI protein accession code CAB89450.1 GI:7672261 putative secreted protein. [Streptomyces coelicolor A3(2)]; Figure 23 shows an amino acid sequence (SEQ ID No. 13) Scoe5 NCBI protein 30 accession code CAB62724.1 GI:6562793 putative lipoprotein [Streptomyces coelicolor A3(2)]; WO 2006/008508 PCT/GB2005/002823 84 Figure 24 shows an amino acid sequence (SEQ ID No. 14) Sriml NCBI protein accession code AAK84028.1 GI:15082088 GDSL-lipase [Streptomyces rimosus]; Figure 25 shows an amino acid sequence (SEQ ID No. 15) of a lipid acyltransferase 5 from Aeromonas salmonicida subsp. Salmonicida (ATCC#14174); Figure 26 shows a TLC (solvent 4) of sample 1 to 10 of crude soya oil treated 20 hours with enzymes according to Table 4. PC is phosphatidylcholine added in 5 different concentrations (reference material). 10 Figure 27 shows a TLC (Solvent 5) of reaction products from lipid acyl transferase or Lecitase UltraTM treatment of crude soya oil samples according to Table 4 (20 hours). Cholesterol ester (CHL-ester), Mono-di-Triglyceride (MONO/D1frRI), and plant sterol were also analysed as references. Identification of free fatty acid is also 15 indicated. Figure 28 shows SEQ ID No 17 which is the amino acid sequence of a lipid acyltransferase from Candida parapsilosis; 20 Figure 29 shows SEQ ID No 18 which is the amino acid sequence of a lipid acyltransferase from Candida parapsilosis; Figure 30 shows alignment 1; 25 Figure 31 shows SEQ ID No. 19. Scoel NCBI protein accession code CAB39707.1 GI:4539178 conserved hypothetical protein [Streptomyces coelicolor A3(2)]; Figure 32 shows an amino acid sequence (SEQ ID No. 25) of the fusion construct used 30 for mutagenesis of the Aeromonas hydrophila lipid acyltransferase gene.. The underlined amino acids is a xylanase signal peptide; WO 2006/008508 PCT/GB2005/002823 85 Figure 33 shows a polypeptide sequence of a lipid acyltransferase enzyme from Streptomyces (SEQ ID No. 26); Figure 34 shows a polypeptide sequence of a lipid acyltransferase enzyme from 5 Thermobifida(SEQ ID No. 27); Figure 35 shows a polypeptide sequence of a lipid acyltransferase enzyme from Thermobifida..(SEQ ID No. 28); 10 Figure 36 shows a polypeptide of a lipid acyltransferase enzyme from Corynebacterium efficiens GDSx 300 amino acid..(SEQ ID No. 29); Figure 37 shows a polypeptide of a lipid acyltransferase enzyme from Novosphingobium aromaticivorans GDSx 284 amino acid_(SEQ ID No. 30); 15 Figure 38 shows a polypeptide of a lipid acyltransferase enzyme from Streptomyces coelicolor GDSx 269 aa (SEQ ID No. 31) Figure 39 shows a polypeptide of a lipid acyltransferase enzyme from Streptomyces 20 avermitilis \ GDSx 269 amino acid (SEQ ID No. 32); Figure 40 shows a polypeptide of a lipid acyltransferase enzyme from Streptomyces (SEQ ID No. 33); 25 Figure 41 shows a ribbon representation of the I1VN.PDB crystal structure which has glycerol in the active site. The Figure was made using the Deep View Swiss-PDB viewer; Figure 42 shows lIVN.PDB Crystal Structure - Side View using Deep View Swiss 30 . PDB viewer, with glycerol in active site - residues within 1 A of active site glycerol are coloured black; WO 2006/008508 PCT/GB2005/002823 86 Figure 43 shows alignment 2; Figure 44 shows an amino acid sequence (SEQ ID No. 34) obtained from the organism Aeromonas hydrophila (P10480; GI:121051) (notably, this is the mature sequence). 5 Figure 45 shows the amino acid sequence (SEQ ID No. 35) of a mutant Aeromonas salmonicida mature lipid acyltransferase (GCAT) (notably, this is the mature sequence) 10 Figure 46 shows a nucleotide sequence (SEQ ID No. 36) from Streptomyces thermosacchari Figure 47 shows an amino acid sequence (SEQ ID No. 37) from Streptomyces thermosacchari 15 Figure 48 shows an amino acid sequence (SEQ ID No. 38) from Thermobgifda fisca/GDSx 548 amino acid Figure 49 shows a nucleotide sequence (SEQ ID No. 39) from Thermobifidafusca 20 Figure 50 shows an amino acid sequence (SEQ ID No. 40) from Thermobgfida fisca/GDSx Figure 51 shows an amino acid sequence (SEQ ID No. 41) from Corynebacterium efficiens/GDSx 300 amino acid 25 Figure 52 shows a nucleotide sequence (SEQ ID No. 42) from Corynebacterium efficiens Figure 53 shows an amino acid sequence (SEQ ID No. 43) from S. coelicolor/ GDSx 30 268 amino acid WO 2006/008508 PCT/GB2005/002823 87 Figure 54 shows a nucleotide sequence (SEQ ID No. 44) from S. coelicolor Figure 55 shows an amino acid sequence (SEQ ID No. 45) from S. avermitilis 5 Figure 56 shows a nucleotide sequence (SEQ ID No. 46) from S. avermitilis Figure 57 shows an amino acid sequence (SEQ ID No. 47) from Thermobipfda fusca/GDSx 10 Figure 58 shows a nucleotide sequence (SEQ ID No. 48) from Thermobqida fusca/GDSx Fig 59 shows TLC (Solvent 4) of reaction products from enzyme treatment of crude soya oil samples according to table 6. As reference, phosphatidylcholine (PC) was also 15 analysed. PE (phosphatydylethanolamine(PE) and lysophosphatidylcholine (LPC) are also indicated. Fig 60 shows TLC (Solvent 5) of reaction products from enzyme treatment of crude soya oil samples according to table 6. References Cholesterolester, mono-di 20 triglyceride and plant sterol. Free fatty acid (FFA) is also indicated Figure 61 shows an alignment of the L131 and homologues from S.avennitilis and T.fisca illustrates that the conservation of the GDSx motif (GDSY in L131 and S.avermitilis and T.fusca), the GANDY box, which is either GGNDA or GGNDL, and 25 the HPT block (considered to be the conserved catalytic histadine). These three conserved blocks are highlighted EXAMPLES 30 The purpose of this study was to investigate the possible use of a lipid acyltransferase (sometimes referred to herein as a glycerophospholipid Cholesterol Acyl-Transferase WO 2006/008508 PCT/GB2005/002823 88 (GCAT)) for degumming of vegetable oil like soya bean oil, sunflower oil and rape seed oil. One purpose of this study was to investigate whether in particular a lipid 5 acyltransferase mutant (N80D) is a more suitable enzyme for degumming. From earlier studies it is known that lipid acyltransferases (particularly GCATs) catalyse the acyl-transfer of fatty acid from phospholipid to sterols to form lysolecithin and sterol esters. 10 The present study was conducted in a model based on refined soya bean oil where phosphatidylcholine and plant sterols were added. This model was selected because it is easier to analyse reaction product in a model system instead of using crude soya oil. Enzymatic degumming processes of plant oils including soya oil and rape seed oil is 15 expanding in recent years because this process is a cheaper and better process to remove lecithins from oil. The enzyme used for oil degumming is a phospholipase Al (Lecitase UltraTm or pancreatic phospholipase A2 - Novozymes A/S, Denmark). One advantage of the enzyme of the present invention when used in degumming 20 compared with prior art phospholipase Al is that the enzyme according to the present invention facilitates the formation of sterol esters during the degumming process and contributes to the accumulation of sterol esters, which is not achieved with the currently used phospholipase Al (Lecitase Ultra

T

"). 25 Materials and methods. Enzymes * Lipid acyltransferase according to the present invention: Aeromonas salmonicidae enzyme with a mutation Asn80Asp (amino acid 80 of the mature 30 enzyme) (SEQ ID No. 16 (see Figure 10)); * Lecitase Ultra (#3108) from Novozymes, Denmark WO 2006/008508 PCT/GB2005/002823 89 Soya bean oil: Soya olie IP (Item No. 005018/ batch nr T -618-4) Lecithin: L-a Phosphatidylcholine 95% Plant (Avanti #441601) Plant Sterol: Generol 122 N from Henkel, Germany. Tocopherol: Alpha-tocopherol ( Item no. .050908/lot.nr 4010140554) 5 Phospholipase activity Substrate 0.6% L-a Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 (Sigma X-100) and 5 mM CaC 2 was dissolved in 0.05M HEPES buffer pH 7. 10 Assay procedure: 400 sl substrate was added to an 1.5 ml Eppendorf tube and placed in an Eppendorf Thermomixer at 37"C for 5 minutes. At time T= 0 min, 50pl enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 10*100 rpm in an Eppendorf Thermomixer at 37*C for 10 minutes. At time 15 T=10 min the Eppendorf tube was placed in another thermomixer at 99"C for 10 minutes to stop the reaction. Free fatty acid in'the samples was analyzed by using the NEFA C kit from WAKO GmbH. Enzyme activity PLU-NEFA pH 7 was calculated as micromole fatty acid produced 20 per minute under assay conditions. HPTLC Applicator: Automatic TLC Sampler 4, CAMAG HPTLC plate: 20 x 10 cm, Merck no. 1.05641. Activated 30 min. at 160*C before use. 25 Application: 1 pl of a 8% solution of oil in buffer is applied to the HPTLC plate using Automatic TLC applicator. Running buffer 1: P-ether : Methyl-tert-butyl-ether : Acetic acid 60:40:1 Running buffer 4: Chloroform:Methanol:Water 75:25:4 Running buffer 5: P-ether : Methyl-tert-butylether : Acetic acid 70:30:1 30 Application/Elution time: Running buffer 1: 12 min Running buffer 4: 20 mn WO 2006/008508 PCT/GB2005/002823 90 Running buffer 5: 10 min Developing The plate is dried in an oven at 160 0 C for 10 minutes, cooled, and dipped into 6% 5 cupri acetate in 16% H 3

PO

4 . Dried additionally 10 minutes at 160*C and evaluated directly. EXAMPLE 1: Enzyme purification 10 Sample: The sample lipid acyltransferase (Asn8OAsp) (SEQ ID No. 16) was filtered through 0.8/0.22 pm filter. 510 ml filtrate was collected. Step 1. Desalting, Sephadex 25 G, 3.21 gel (10 cm id) The Sephadex column was prepared as described by the manufacturer (Amersham 15 biosciences). The column was equilibrated with 20 mM Na-P-buffer, pH 8.0. The sample (510 ml) was applied to the column at a flow rate of 25 nil/min. 815 ml desalted sample was collected and kept at +4 0 C. Step 2. Anion exchange chromatography, Q-Sepharose FF 300 ml gel (XK 50) 20 Q-Sepbarose FF column was prepared as described by the manufacturer (Amersham biosciences). The column was equilibrated with 20 mM Na-P-buffer, pH 8.0. The desalted sample was applied to the column at a flow rate of 15 ml/min. The column was then washed with buffer A. The lipase was eluted with a linear gradient of 0-0.4 M NaCl in 20 mM Na-P-buffer (pH 8.0, buffer B). Fractions of 15 ml were collected 25 during the entire run. The lipase was eluted at approx. 0.2 M NaCl, and no lipase activity was detected in running through fractions. Enzyme Assay based on PNP-caprylate The assay was performed using PNP-Capylate as substrate as follows: 30 10 mg of substrate solved in I ml ethanol and was mixed with 9 ml of 50 mM Tris HCL buffer (pH 7.3) containing 0.4% TX1 00.

WO 2006/008508 PCT/GB2005/002823 91 240 pl of substrate was pre-incubated at 35 degree C. The reaction was initiated by the addition of 25 pl of sample/blank. The mixture was incubated at 35*C for 5 min with shaking. Using a spectrophotometer, the formation of PNP was measured continually at 410 nm. The blank run contains all the components with buffer instead of sample. 5 One unit of lipase activity was defined as the amount of enzyme releasing 1 pl of free caprylic acid per minute at 35*C. Determination of molecule weight and purity. SDS-PAGE was carried out on a 4-12% Nu-PAGE gel (+DTT) and Coomassie stained 10 according to the manufacturers instructions (Novex, USA). The standard marker was See Blue Plus2 and was obtained from Novex, USA. Results 15 The chromatogram from Ion Exchange Chromatography (IEC) purification of the lipid acyltransferase mutant N80D is shown in Fig. 1. The fractions collected were analyzed for lipase activity (based on PNP-Caprylate assay). The activity of the fractions is illustrated in Fig 1-a. 20 The fractions containing lipid acyltransferase activity (27-39, 195 ml) were pooled. The final recovery of the partly purified lipid acyltransferase was approx. 80% (based on pNP-Caprylate assay). 25 Fractions of the purified lipid acyltransferase were subjected to SDS-PAGE gel electrophoresis. The SDS-PAGE gel revealed lipid acyltransferase protein with a molecular weight of approx. 28 KDa. The partly purified lipid acyltransferase contained a minor impurity 30 at approx 10 KDa (see Figure 2).

WO 2006/008508 PCT/GB2005/002823 92 The lipid acyltransferase pool 27-39 after IEC was analysed for phospholipase activity with the result of 20.4 PLU-7/ml. The overall purification scheme is presented in Table 1, in which the lipid 5 acyltransferase was partly purified with a recovery of 80%. Table 1. Purification of the lipid acyltransferase Sample Vol. Vm,, Dilution Tot. Units %Recovery 10 Crude (Q3+Q4) 510 1.150 100 58650 100 Desalted crude 815 0.697 100 56806 97 Pool 27-39, Q-Sep. 195 1.203 200 46898 80 15 EXAMPLE 2: Degumming experiment The lipid acyltransferase sample from Example 1 was used for degumming studies in the formulations shown in Table 2. 20 Plant sterol, alpha-tocopherol and phosphatidylcholine were dissolved in soya bean oil by heating the oil to 90 *C. The oil was then cooled to approx 40 *C and the enzyme was added. The sample was placed at 40 *C for 17 hours during agitation and then a sample was taken out for HPTLC analysis by dissolving the sample in Chloroform 25 :Methanol 2:1. 30 WO 2006/008508 PCT/GB2005/002823 93 Table 2. Soya bean oil models with alpha-tocopherol and plant sterol, used for testing of the lipid acyltransferase. 1 2 3 4 5 6 7 8 9 10 Soya bean oil % 98 97 97 96 97 96 96 95 96 92 Alpha-tocopherol % 1 1 1 1 1 1 Plant Sterol % I 1 1 1 1 1 Phosphatidylcholine % 2 2 2 2 2 2 2 2 2 2 lipid acyltransferase pool 27-39 % 1 1 1 1 4 The results from the HPTLC analysis are shown in Figure 3 and Figure 4. 5 The TLC results shown in Figure 3 clearly show that phosphatidylcholine is almost 100% removed by adding the lipid acyltransferase to the oil. Only sample no. 10 contains small amount of phosphatidylcholine. Sample no. 10 has the highest amount of water, which indicates that for degumming the enzyme may work better in low 10 water formulations, or it could be explained by the fact that because sample no. 10 contain 5% water a two-phase system is formed, which might cause less contact between the reactants and the enzyme. From the results shown in Figure 4 is was observed that small amount of fatty acids 15 are formed, but when sterol or alpha-tocopherol is also available in the oil the amount of free fatty acids is lower, because the fatty acids from phosphatidylcholine it transferred to the sterol or tocopherol to form sterol-esters and tocopherol-esters. The formation of sterol esters is clearly seen from the TLC results shown in Figure 5. 20 It should be noted that the reference material used, cholesterol ester, has the same retention time as plant-sterol-esters. 25 WO 2006/008508 PCT/GB2005/002823 94 EXAMPLE 3: Degumming experiment (2) In another experiment the lipid acyltransferase pool 27-39 from IEC chromatography, was tested at different enzyme dosages and water concentrations in soya bean oil with 5 phosphatidylcholine and plant sterol. In this experiment a commercial phospholipase Lecitase UltraTm was also tested in a concentration recommended by the supplier for degumming. The composition of the samples for this experiment are shown in Table 3. Table 3. Soya bean oil model with plant sterol used for testing of the lipid 10 acyltransferase, and Lecitase UltraTm. 1 2 3 4 5 6 7 8 9 10 Soya bean oil % 96,6 96,6 96 92 96 92 95 92 96 92 Plant Sterol % 1 1 1 1 1 1 1 1 1 Phosphatidylcholine % 2 2 2 2 2 2 2 2 2 2 Lipid acyltransferase pool 27-39 % 0,4 0,4 0,4 1 1 2 2 Lecitase UltraTm, 1% solution % 0,3 0,3 Water 0,4 0,6 4,6 0 4 0 3 0,7 4,7 Units /g oil (PLU-7/g) 0 0,08 0,08 0,08 0,2 0,2 0,4 0,4 1,03 1,03 Plant sterol and phosphatidylcholine were dissolved in soya bean oil by heating to 95*C during agitation. The oil was then cooled to 40 *C and the enzymes were added. The sample was maintained at 40 0C with magnetic stirring and samples were taken 15 out after 4 and 20 hours and analysed by TLC. The results from the HPTLC analysis of samples taken out after 4 and 20 hours are shown in Figures 6 to 9. The HPTLC results indicate that the lowest dosage of the lipid acyltransferase (0.4% corresponding to 0.08 PLU-7/g oil) is sufficient to remove phosphatidylcholine in soya 20 bean oil after 20h reaction time. It is also observed that the highest dosage of water (5%) seems to have a detrimental effect on the lipid acyltransferase for the hydrolysis of phosphatidylcholine in the oil. It is therefore expected that the lower degree of WO 2006/008508 PCT/GB2005/002823 95 hydrolysis in the sample with highest dosage of the lipid acyltransferase conversion is explained by that fact that more water is also added to the sample. Contrary to this it is observed that Lecitase UltraTm has a lower degree of hydrolysis of phosphatidylcholine in the lowest dosage of water (1%), whereas Lecitase UltraTm almost completely 5 removes phosphatidylcholine in the sample with 5% water. The results from Figure 7 also indicate that the main part of the plant sterol is converted to plant sterol ester in samples treated with the lipid acyltransferase whereas no sterol esters are formed in the samples treated with Lecitase Ultram. Figure 7 10 indicates that Lecitase UltraTM produce more free fatty acids (FFA) than the lipid acyltransferase. Conclusion 15 Degumming experiments with a model soya bean oil containing phosphatidylcholine, plant sterol and tocopherol has shown that a partially purified lipid acyltransferase enzyme is able to remove all phosphatidylcholine concomitant with the formation of plant sterol esters, and only to a small extent free fatty acids are formed. 20 One further advantage of the lipid acyltransferase is the formation of sterol esters, and in particular tocopherol ester, because sterols esters (including tocopherol ester) provide beneficial health properties. In conventional edible oil processing, following degumming the aqueous phase containing the hydrolysed polar lipid (e.g. phospholipid and/or glycolipid) is separated from the oil. Conventionally sterols are removed from 25 the edible oil during the oil refining process (this is sometimes referred to as deodorising). . However, the sterol esters (and tocopherol ester) resist deodorisation and thus remain in the oil. Accumulation of sterol esters in the oil is attractive because it has been shown that higher intake of plant sterol esters reduces the risk for cardiovascular diseases in humans. 30 The experiment also indicates that the lipid acyltransferase is able to make tocopherol esters, which will also accumulate in the oil.

WO 2006/008508 PCT/GB2005/002823 96 This will contribute to improved oxidative stability of the oil and thus is a further benefit to using the lipid acyltransferase in accordance with the present invention for degumming. 5 EXAMPLE 4: Degumming experiment in crude oil In another experiment, the lipid acyltransferase pool 27-39 from IEC chromatography was tested at different enzyme dosages and water concentrations in crude soya oil 10 (before degumming) obtained from The Solae Company, Aarhus, Denmark. In this experiment, a commercial phospholipase Lecitase UltraTM was also tested in a concentration recommended for degumming by the supplier. The composition of the samples for this experiment is shown in Table 4. 15 The samples were placed in a heating block at 40 *C during agitation with a magnetic stirrer. Samples were taken out after 20 hours for analysis. Table 4 1 2 3 4 5 6 7 8 9 10 Crude soya oil % 99,5 99,5 99 98 97 98 95 99,7 99 Lipid Acyltransferase % 0,5 1 1 1 2 5 Lecitase UltraTm #3108, 1% solution % 0,3 0,3 0,3 Water % 0,5 0 0 1 2 0 0 0 0,7 4,7 20 The oil samples were analysed by HPTLC with the results shown in Figure 26 and 27. The TLC analysis in Figure 26 indicate that the lipid acyltransferase efficiently removes the phospholipids in crude soya oil without leaving any lysolecithin in the 25 sample (sample 3, 4, 6 and 7). Lecitase UltraTm also removes the phospholipid (PC), WO 2006/008508 PCT/GB2005/002823 97 but some bands are remaining in the chromatogram, which is expected to be lysolecithin. It is also observed that lipid acyltransferase works in very low water environment, but Lecitase UltraTm needs 1% to 5% water to work. 5 The results in Figure 27 confirm that lipid acyl transferase converts the free sterol to sterolesters and Lecitase UltraTM has no effect on sterols. Figure 27 also indicates that some free fatty acids are formed both in samples with lipid acyl transferase and Lecitase Ultra T M . The reason for the free fatty acid formation with lipid acyl transferase is explained by the fact that there is not enough acyl-donor (sterol) 10 available, and therefore some hydrolysis also occurs. Sample 1, 2, 3, 6, 8 and 10 from table 4 were analysed by GLC and the amount of sterol and sterol esters were quantified. The results are shown in Table 5. 15 Table 5. GLC analysis of sterol and sterol esters In crude soya oil treated with enzyme (Table 4) Sample Enzyme Sterol Sterolester no% % I Control 0,25 0,07 2 0,5% Lipid acyltransferase pool 27-39 0,13 0,13 3 1% Lipid acyltransferase pool 27-39 0 0,26 6 2% Lipid acyltransferase pool 27-39 0 0,22 8 0,3% Lecitase UltraTm 1% solution 0,25 0,03 10 0,3% Lecitase UltraTM 1% solution+ 5% water 0,27 0,05 The results in Table 5 confirm the ability of the lipid acyl transferase of the present invention to convert all sterol in crude soya oil to sterol ester, and a commercial 20 phospholipase Lecitase UltraTm showed no effect on sterol.

WO 2006/008508 PCT/GB2005/002823 98 CONCLUSION The effect of the lipid acyl transferase of the present invention on crude soya oil confirms that the lipid acyl transferase of the present invention effectively removes 5 phospholipids in the crude soya oil concomitant with the formation of sterol esters. Example 5 In another experiment, phospholipase from Streptomyces thermosacchari L131 was 10 tested in crude soya oil. The results confirm that phospholipase Streptomyces thermosacchari L131 effectively hydrolyses phospholipids in crude soya oil and is a suitable alternative enzyme for degumming of plant oils. 15 Enzymatic degumming processes of plant oils including soya oil and rape seed oil are currently expanding because this process is a less expensive and better process to remove lecithins from plant oils. The enzyme commercially used for oil degumming is a microbial phospholipase Al or an animal derived phospholipase A2. 20 A (phospho)lipid acyl transferase Streptomyces thermosacchari L131 is another enzyme, which can be used for degumming. Introduction 25 The purpose of this study was to investigate the possible use of a lipid acyltransferase from Streptomyces thermosacchari L131 for degumming of vegetable oil like soya oil, sunflower oil, and rape seed oil. 30 Traditionally, two processes have been used for degumming of oils, namely the physical degumming and the chemical degumming. Back in the 1990'es, the WO 2006/008508 PCT/GB2005/002823 99 enzymatic degumming process was developed, based on the use of pancreatic phospholipase. Because this enzyme was non-kosher, the phospholipase was substituted by microbial phospholipase Al. The enzymatic process has several advantages over the chemical or the physical degumming processes including cost 5 savings, higher yield, and a more environmentally desirable process. The purpose of this study was to investigate whether lipid acyltransferase from Streptomyces thermosacchari L131 would be a suitable enzyme for degumming. From the studies described above Streptomyces thermosacchari L131 is known to have 10 hydrolytic properties against galactolipids and phospholipids without showing any activity on triglycerides, and it is expected that this enzyme also facilitates transferase reactions in certain environments with low water content. This study was conducted in crude soya oil with the natural content of phospholipids. 15 Materials and methods Enzyme K371( jour 2390-30): Streptomyces thermosacchari L131 IS. lividans freeze dried on starch. (Activity: 108 PLU-7/g). 20 Lecitase Ultra (#3108) from Novozymes, Denmark Cholesterolester, Fluka 26950 Plant Sterol: Generol 122 N from Henkel, Germany Crude soya oil from The Solae Company, Aarhus Denmark 25 Lecithin: L-a Phosphatidylcholine 95% Plant (Avanti #441601) Phospholipase activity Substrate: 0.6% L-ox Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 30 (Sigma X-100), and 5 mM CaCl 2 were dissolved in 0.05M HEPES buffer pH 7. Assay procedure: WO 2006/008508 PCT/GB2005/002823 100 400 pl substrate was added to a 1.5 ml Eppendorf tube and placed in an Eppendorf Thermomixer at 37*C for 5 minutes. At time T= 0 min, 50pl enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 10*100 rpm in an Eppendorf Thermomixer at 37*C for 10 minutes. At time 5 T=1 0 min the reaction was stopped by placing the Eppendorf tube in another thermomixer at 99 0 C for 10 minutes. The free fatty acid content of samples was analyzed by using the NEFA C kit from WAKO GmbH. Enzyme activity PLU-NEFA pH 7 was calculated as micromole fatty acid produced 10 per minute under assay conditions. GLC (Gas Chromatography) Perkin Elmer 8420 Capillary Gas Chromatography equipped with WCOT fused silica 15 column 12.5 m x 0.25 mm ID x 0.1 pm 5%phenyl-methyl-silicone (CP Sil 8 CB from Crompack). Carrier: Helium. Injection: 1.5 tL with split. Detector: FID. 385 *C. 20 Oven program: 1 2 3 4 Oven temperature [*C] 80 200 240 360 Isothermal, time [min] 2 0 0 10 Temperature rate [*C/min] 20 10 12 25 Sample preparation: Lipid extracted from 0,2 gram sample was dissolved in 2 mL heptane: pyridine 2:1 containing an internal standard heptadecane, 2 mg/mL. 500 pL of the sample was transferred to a crimp vial. 100 pL MSTFA (N-Methyl-N trimethylsilyl-trifluoracetamid) was added and the reaction incubated for 15 minutes at 90 0 C. 30 WO 2006/008508 PCT/GB20051002823 101 HPTLC Applicator: Automatic TLC Sampler 4, CAMAG HPTLC plate: 20 x 10 cm, Merck no. 1.05641. Activated 30 minutes at 160*C before use. 5 Application: 1 pl of a 8% solution of oil in buffer was applied to the HPTLC plate using Automatic TLC applicator. Running buffer 4: Chloroform:Methanol:Water 75:25:4 Running buffer 5: P-ether : Methyl-tert-butyl-ether : Acetic acid 70:30:1 10 Application/Elution time: Running buffer 4: 20 min Running buffer 5: 10 min 15 Development The plate was dried in an oven for 10 minutes at 160*C, cooled, and dipped into 6% cupri acetate in 16% H 3

PO

4 . Dried additionally 10 minutes at 160 0 C and evaluated directly. 20 Results. Degumming experiment. Streptomyces thermosacchari L131 was used for degumming studies in the formulations shown in table 6. 25 The samples were placed at 40*C for 18 hours with agitation, after which time a sample was collected for HPTLC analysis by dissolving the sample in Chloroform :Methanol 2:1 30 WO 2006/008508 PCT/GB2005/002823 102 Table 6. Degumming of crude soya oil with Streptomyces thermosacchari L131 And Lecitase Ultra 1 2 3 4 5 6 Crude soya oil % 99 99 98 97 99,7 99 K371, 10% in water % 1 2 3 Lecitase UltraTm #3108, 1% in water % 0,3 0,3 Water % 1 0 0 0 0,7 The results from the HPTLC analysis are shown in fig. 59 and 60. 5 Fig 59 TLC (Solvent 4) of reaction products from enzyme treatment of crude soya oil samples according to table 6. As reference, phosphatidylcholine (PC) was also analysed. PE (phosphatydylethanolamine(PE) and lysophosphatidylcholine (LPC) are also indicated. 10 Fig 60 TLC (Solvent 5) of reaction products from enzyme treatment of crude soya oil samples according to table 6. References Cholesterolester, monoglyceride, diglyceride, triglyceride and plant sterol. Free fatty acid (FFA) is also indicated 15 The TLC results in Figure 59 clearly show that phosphatidylcholine was completely removed by adding Streptomyces thermosacchari L131 to the oil. Only the lowest dosage (sample 2) did not completely hydrolyse the phospholipids. Lecitase UltraTm also hydrolysed the phospholipids in the oil when 5% water was available (sample 6) but without adding extra water (sample 5) only part of the phospholipids were 20 hydrolysed. The results shown in fig. 60 indicate that the hydrolysis of phospholipids is coincident with the formation of free fatty acid. 25 Conclusion.

WO 2006/008508 PCT/GB2005/002823 103 The lipid acyltransferase from Streptomyces thermosacchari L131 effectively hydrolysis phospholipids in crude soya oil during formation of free fatty acids. All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present 5 invention will be apparent to those skilled in the art without departing from the scope of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in LO biochemistry and biotechnology or related fields are intended to be within the scope of the following claims. Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of 15 integers. Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirely by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent 2o application, or patent cited in this text is not repeated in this text is merely for reasons of conciseness. Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general knowledge or 25 was known in Australia or any other country.

WO 2006/008508 PCT/GB2005/002823 104 kIUDAPEST TREATY ON THE WERNAIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM DMnbco AS RECEIPTIN THE CASE OF AN ORIGINAL DEPOSIT IagcbroEE de I Issued pursuant to Rule 7.1 by the DK-1001 Copenhagen INTERNATIONAL DEPOSITARY AUTHORITY . Danmark Identified at the bottom of this page NAME AND ADDRESS OF DEPOSITOR L IDENTIFICATION OF THE MICROORGANISM Identification reference given by the Accession number given by the DEPOSfOR' ITERNATIONAL DEPOSITARY AUIROR1TY: FAcherichia coil NMB 41204 TOP1OpPet12aAbydro U. SCENTI FIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The mieroorganism Identified under I above was accompanied by [Ii a scientific description a proposed taxonomic designation (Mark with a cross where applicable) IM. .RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under I above, whichwas received byit on 22 Decernber 2003 (date of the original deposit)' IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism Identified under I above was received by'this international Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest 'neaty was received by It on (date of receipt of request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY Nam=: NCIMB Ltd., Signature(s) ofperson(s) having the power to represent the International Depositary Authority or of authorised - offciaI(s): Address: 23 St Macbar Drive. Aberdeen Date: 9 January2004 AB24.3RY Scotland, UK. a Where Rule 6/4(d) applies, such date is the date on which the status of InterationaJ Depositary Authority was V- e PAred --- WO 2006/008508 PCT/GB20051002823 105 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR TBE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM Danisco.A/S VIABILITY STATEMENT I issued pannant to n 10.2 by the DK-1001 Copenhagen INTERNATIONAL DEPOSITARY AUTHORITY Denmark .identified on the following Pve NAME AND ADDRESS OF THE PARTY TO WHOM THE VIABILITY STATEME T ISISSUED 1. DEPOSITOR U. IDEFIMCATION OF THE MICROORGANISM Nam: - AS ABOVE Accession number given by the INTERNA'HONAL DEPOSITARY AUTHORITY: Address: NCIMB 41204 Date of the deposit or of the transfer': 22 December2003 IM. VIABIUlTY STATEMENT The viability of the microorganisn identified under 1I above was tested on 22 December 2003 2 On that date, the said microorganisn E l viable no longer viable Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer) 2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test. Mark with a cross the applicable box. Form BP)9 (first page) WO 2006/008508 PCT/GB2005/002823 106 IV. CONDITIONS UNDER WHICH THE VIABIUTY TEST HAS BEEN PERFORME. V. TERNATIONAL DEPOSITARY AUTHORITY Name: NCIMB Ltd., Signature(s) of person(s) having the power to represent the International Depositary Address 23 St MacharDrive Authority or of authorised official(s): Aberdeen AB24 3RY <-q. ... Scotland . Date: 9 January 2004 4 Fill in if the information has been requested and if the results of the test were negative. Form BP/9 (second and last page) WO 2006/008508 PCT/GB2005/002823 107 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE. INTERNATIONAL FORM Danisco A/S RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT Langebrogade I Issued pursuant to Rule 7.1 by the DK-1001 Copenhagen INTERNATIONAL DEPOSITARY AUTBORMIY Denmark Identilled at the bottom of this page NAME AND ADDRESS OF DEPOSITOR L IDENTIFICATION OF THE MICROORGANISM Identification referenc'give by the Accession number given by the DEPOSrrOL INTERNATIONAL DEPOSITARY AUITHORTIY: Eschericha coU 'NCIMB 41205 TOPI0pPet12aAsabno II. SCIEN FIC DESCRIPTON AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I above was accompanied by. a scientific description a proposed taxonomic designation (Mark with a cross where applicable) Ill. RECEIPT AND ACCEPTANCE 'This Intenational Depositary Authority accepts the microorganism identified under I above, which was received by it on 22 December 2003 (date of the original deposit)' IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International DepositaryAuthority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Teaty was received by it on (date of receipt of request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY Name: NCIMB Ltd., Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s): Address 23 St Machar Drive Aberdeen Date: 9 January 2004 AB24 3RY Scotland, UK. Where Rule 6/4(d) applies, such date is-the date on which the status of International Depositary Authority was acquired. Form BP/4 (sole naael WO 2006/008508 PCT/GB2005/002823 108 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM Danisco AS . VIABILITY STATEMENT Langebrogade I Issued pursent to Rule 10.2 by the DK-1001 Copeagen INTERNATIONAL DEPOSITARY AUTHORITY Denmak Identiled on the following page NAME AND ADDRESS OF TIE PARTY TO WHOM THE VIABrLTY STATEMENT IS ISSUED 1. DEPOSITOR U. MENTCAF ON OF THE NCROORGANISM Name: AS ABOVE Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Addrew NCIMB 41205 Date of the deposit or of the transfer':, 22 December 2003 IM. VIABILITY STATEMENT The viability of the microorganism identified under D above was tested on 22 December 2003 2. On that date, the said icoorganis. viable no longer viable. 2 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer). 2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test. 3 Mark with a aoss thd applicable box. Fonm BP/9 (fist page) WO 2006/008508 PCT/GB2005/002823 109 TV. CONDITIONS UNDER WHICH THE VIABILITM ET HAS BEEN4 PEURIMVD V. INTERNATIONAL DEPOSITARY AUTHORMl NaMm NC[MB lAd., Signature(s) of pcson(s) having the power to reprsent the hIternational Depositary AddressE 23 St Macbar Drive Authority orofautorised official(s): Aberdeen AB24 3RY rL.I)- Scotland DatL- 9 January 2004 4 Fill in if the information has been requested and if thc* results of the test were negative. Form BP/9 (second and last page) WO 2006/008508 PCT/GB2005/002823 110 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR TEE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM Danisco Intellectual Assets RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT Danisco A/S Issued pursuant to Rule 7.1 by the Langebrogade I INTERNATIONAL DEPOSITARY AUTHORITY DK-101 CpenhgenIdentiffed at the bottom of this page DK-1001 Cpengen Denmak NAME AND ADDRESS OF DEPOSHOR L IDENTIFICATION OF THE MICROOROANISM Identification reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY AUTHORITY: Streptomyces sp. NCIMB 41226 L130 IL SCIENT1 FIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I above was accompanied by: D a scientific description W a proposed taxonoinic designation (Mark with a mss where applicable) I3. RECEIPT AND ACCEPTANCE This International Depositary Authority accets the microorganism identified under I above, which was received by it on 23 June 2004 (date of the original deposit) IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY Name: NCIMB Ltd, Signatre(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s): Address: 23 St Machar Drive dC- I Aberdeen Date: 28 June 2004 AB24 3RY Scotland, UK. Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired. Form BP/4 (sole page) WO 2006/008508 PCT/GB2005/002823 111 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF TEE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM Danisco Intellectual Assets VIABILITY STATEMENT Issued pursuant to Rule 10.2 by the Danisco AS INTERNATIONAL DEPOSITARY AUTHORITY Langebrogade I Identiied on the following page DK-1001 Copenhagen Denmark NAME AND ADDRESS OF THE PARTY TO WHOM THE VIABRITY STATEMENT IS ISSUED L DEPOSITOR H. IDENTIFICATION OF THE MICROORGANISM Name: AS ABOVE Accession number given by the INTERNATIONAL DEPOSITARY AUTHORiTY: Address: NCIMB 41226 Date of the deposit or of the transfer': 23 June 2004 M. VIABILITY STATEMENT The viability of the microorganism identified under H above was tested on 25 June 2004 2. On that date, the said microorganism was: viable no longer viable Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the tansfe4 2 In the cases referred to in Rule 10.2(aXii) and (iii), refer to the most recent viability test. 3 Mark with a cross the applicable box. Form BP/9 (first page) WO 2006/008508 PCT/GB2005/002823 112 IV. CONDITIONS UNDER WHICH THE VIABIIY IEST HAS BEEN PERFORMED. V. INTERNATIONAL DEPOSITARY AUTHORITY Name NCIMB Ltd., Signature(s) of person(s) having the power to represent the International Depositary Address: 23 St Machar Drive Authority or of authorised officialss: Aberdeen AB24 3RY Scotland Date: 2g June 2004 * Fill in if the information has been requested and if the results of the test were negative. Form BP/9 (second and last page) WO 2006/008508 PCT/GB2005/002823 .113 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE Danisco Intellectual Assets INTERNATIONAL FORM Danisco A/S RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT Langebrogade 1 issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSrARY AUTHORITY De-1001 Copenhagen Identified at the bottom of this page Denmark NAME AND ADDRESS OF DEPOSI'OR L IDENTIFICATION OF THE MICROORGANISM Identification reference given by the Accession number given by the DEPOSITOR: INTERNATIONAL DEPOSITARY AUTHORITY: Streptomycer Sp. NCIMB 41227 L131 U. SCIENTI FIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I above was accompanied by: D] a scientific description [I] a proposed taxonomic designation (Mark with a cross where applicable) HiL RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 23 June 2004 (date of the original deposit) IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Thaty was received by it on (date of receipt of request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY Nan= NCIMB Ltd., Signature(s) of persons) having the power to represent the International Depositary Authority or of authorised official(s): Address: 23 St Machar Drive /epex9 cxR D Aberdeen Date: 28 June 2004 AB24 3RY Scotland, UK. aire Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired. Form BP/4 (sole page) WO 2006/008508 PCT/GB2005/002823 ~114 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGAISMS FOR THE PURPOSES OF PATENT PROCEDURE INTERNATIONAL FORM Danisco Intellectual Assets Danisco A/S VIABILM STATEMENT Issued pursuant to Rule 10.2 by the Langebrogade 1 INTERNATIONAL DEPOSITARY AUTHORITY DK-1001 Copenhagen Identified on the following page Denmark NAME AND ADDRESS OF THE PARTY TO WHOM TEE VIABIITY STATEMENT IS ISSUED L DEPOSITOR IL IDENTIFICATION OF THE MICROORGANISM Name: AS ABOVE Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Address: NCIMB 41227 Date of the deposit or of the trsfer': 23 June 2003 III. VIABUIIY STATEMENT The viability of the microorganism identified under H above was tested on 25 June 2004 . On that date, the said microorganism was: 3 XI viable no longer viable Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer). 2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viablity test Mark with a cross the applicable box. Form BP/9 (first page) WO 2006/008508 PCT/GB2005/002823 115 IV. CONDOM ONS UNDER WIUCH THE VIAB1LfTY TEST HAS BEEN PERFORMEDf V. INTERNATIONAL DEPOSITARY AUTHORITY Name: NCIMB Ltd., Signature(s) of person(s) having the power to represent the International Depositary Address 23 St Machar Drive Authority or of authorised official(s): Aberdeen.-L - D L ABZ43RY - /.&X ~ Scotland Date: 28 June 2004 ' Fill in if the information has been requested and if the results of the test were negative. Form BP/9 (second and last page)

Claims

1. A process of enzymatic degumming edible oils, comprising treating the edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, wherein the acyl acceptor is one or more 5 sterol and/or stanol.

2. A process according to claim 1 wherein the lipid acyltransferase has or more of the following activities: a) at least 5% acyltransferase activity using the protocol for determination of 10 % acyltransferase assay, wherein the % acyltransferase assay comprises the following steps: i. Reacting an edible oil and a lipid acyltransferase according to the present invention with CHCl3: CH3 OH 2:1; ii. Extracting the organic phase containing the lipid material; 15 iii. isolating and analysing the organic phase by GLC and HPLC, wherein the amount of free fatty acids and one or more of sterol/stanol esters are determined; iv. carrying out steps i to iii with a control edible oil to which no enzyme according to the present invention has been 20 added; v. calculating the increase in free fatty acids and sterol/stanol esters as follows: A % fatty acid = % Fatty acid(enzyme) - % fatty acid(control); Mv fatty acid = average molecular weight of the fatty acids; A = A % sterol ester/Mv sterol 25 ester (where A % sterol ester = % sterol/stanol ester(enzyme) - % sterol/stanol ester(control) and Mv sterol ester = average molecular weight of the sterol/stanol esters); vi. calculating the transferase activity as a percentage of the total enzymatic activity using the formula: 30 % transferase activity = A x 100 A+A % fatty acid/(Mv fatty acid); b) converts at least 1% of the added sterol to sterol-ester as a result of the following steps: i. Dissolving plant sterol and phosphatidylcholine in soya bean oil by heating to 95*C during agitation; 5 ii. Cooling the oil to 40 *C; iii. Adding the enzymes; iv. maintained at 40 IC with magnetic stirring and samples for 4 or 20 hours; and v. analysing the oil by TLC; 10 c) has lipid acyltransferase activity classified under E.C. 2.3.1.x.

3. A process according to claim I or claim 2 wherein the acyl acceptor is a sterol.

4. A process according to any one of the preceding claims wherein the phospholipid 15 is a lecithin.

5. A process according to any one of the preceding claims wherein the lipid acyl transferase, as well as being able to transfer an acyl group from a lipid to a sterol and/or a stanol, additionally transfers the acyl group from a lipid to one or more of 20 a carbohydrate, a protein, a protein subunit, and glycerol.

6. A process according to any one of the preceding claims wherein the lipid acyltransferase is a natural lipid acyltransferase. 25

7. A process according to any one of the preceding claims wherein the lipid acyltransferase is a variant lipid acyltransferase.

8. A process according to any one of the preceding claims wherein said lipid acyltransferase is obtainable from an organism from one or more of the following 30 genera: Aeromonas, Streptomyces, Saccharomyces, Lactococcus, Mycobacterium, Streptococcus, Lactobacillus, Desulfitobacterium, Bacillus, Campylobacter, Vibrionaceae, Xylella, Sulfolobus, Aspergillus, Schizosaccharomyces, Listeria, Neisseria, Mesorhizobiuni, Ralstonia, Xanthomonas, Candida, Thermobifida and Corynebacterium.

9. A process according to any one of the preceding claims wherein said lipid 5 acyltransferase is obtainable from one or more of Aeromonas hydrophila, Aerononas salmonicida, Streptomyces coelicolor, Streptomyces rinosus, Streptomyces thernosacchari, Streptomyces avermitilis, Mycobacteriun, Streptococcus pyogenes, Lactococcus lactis, Streptococcus pyogenes, Streptococcus thermophilus, Lactobacillus helveticus, Desulfitobacterium dehalogenans, Bacillus sp, 10 Campylobacter jejuni, Vibrionaceae, Xylella fastidiosa, Sulfolobus solfataricus, Saccharomyces cerevisiae, Aspergillus terreus, Schizosaccharomyces pombe, Listeria innocua, Listeria monocytogenes, Neisseria meningitidis, Mesorhizobium loti, Ralstonia solanacearum, Xanthomonas campestris, Xanthomonas axonopodis, Candida parapsilosis, Thermobifidafusca and Corynebacterium efficiens. 15

10. A process according to any one of the preceding claims wherein there is less than 1% water in the edible oil during treatment.

11. A process according to any one of the preceding claims wherein the process 20 comprises removing the lysophospholipids produced by the action of the lipid acyltransferase by filtration.

12. Use of a lipid acyltransferase in the degumming of edible oils to remove phospholipids and to increase the formation of sterol esters and/or stanol esters in the 25 oil.

13. Use according to claim 12 where there is no significant increase in the free fatty acids in the oil following treatment. 30

14. Use according to claim 12 or claim 13 wherein the phospholipid is a lecithin. 119

15. Use according to any one of claims 12 to 14 wherein the lipid acyltransferase has or more of the following activities: a) at least 5% acyltransferase activity using the protocol for determination of % acyltransferase assay, wherein the % 5 acyltransferase assay comprises the following steps: i. Reacting an edible oil and a lipid acyltransferase according to the present invention with CHCl3:CH30H 2:1; ii. Extracting the organic phase containing the lipid material; iii. isolating and analysing the organic phase by GLC and 10 HPLC, wherein the amount of free fatty acids and one or more of sterol/stanol esters are determined; iv. carrying out steps i to iii with a control edible oil to which no enzyme according to the present invention has been added; 15 v. calculating the increase in free fatty acids and sterol/stanol esters as follows: A % fatty acid = % Fatty acid(enzyme) - % fatty acid(control); Mv fatty acid = average molecular weight of the fatty acids; A = A % sterol ester/Mv sterol ester (where A % sterol ester = % sterol/stanol 20 ester(enzyme) - % sterol/stanol ester(control) and Mv sterol ester = average molecular weight of the sterol/stanol esters); vi. calculating the transferase activity as a percentage of the total enzymatic activity using the formula: % transferase activity = A x 100 25 A+A % fatty acid/(Mv fatty acid); b) converts at least 1% of the added sterol to sterol-ester as a result of the following steps: vi. Dissolving plant sterol and phosphatidylcholine in soya bean oil by heating to 95'C during agitation; 30 vii. Cooling the oil to 40 'C; viii. Adding the enzymes; ix. maintained at 40 'C with magnetic stirring and samples for 4 or 20 hours; and x. analysing the oil by TLC; c) has lipid acyltransferase activity classified under E.C. 2.3.1.x. 5

16. Use according to any one of claims 12-15 wherein said lipid acyltransferase is obtainable from organisms from one or more of the following genera: Aeromonas, Streptomyces, Saccharomyces, Lactococcus, Mycobacterium, Streptococcus, Lactobacillus, Desulfitobacterium, Bacillus, Campylobacter, Vibrionaceae, Xylella, 10 Sulfolobus, Aspergillus, Schizosaccharomyces, Listeria, Neisseria, Mesorhizobium, Ralstonia, Xanthomonas, Candida, Thermobifida and Corynebacterium.

17. Use according to any one of claims 12-16 wherein the lipid acyltransferase is obtainable from one or more of Aeronionas hydrophila, Aeromonas salmonicida, 15 Streptomyces coelicolor, Streptonzyces rimosus, Streptomyces thernosacchari, Streptomyces avermitilis, Mycobacterium, Streptococcus pyogenes, Lactococcus lactis, Streptococcus pyogenes, Streptococcus thermophilus, Lactobacillus helveticus, Desulfitobacterium dehalogenans, Bacillus sp, Canpylobacter jejuni, Vibrionaceae, Xylella fastidiosa, Sulfolobus solfataricus, Saccharomyces cerevisiae, Aspergillus 20 terreus, Schizosaccharomyces pombe, Listeria innocua, Listeria monocytogenes, Neisseria meningitidis, Mesorhizobium loti, Ralstonia solanacearum, Xanthomonas campestris, Xanthomonas axonopodis Candida parapsilosis, Thermobifidafusca and Corynebacterium efficiens. 25

18. Use according to any one of claims 12-17 wherein there is less than 1% water in the edible oil during treatment.